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 Disorders of iron homeostasis affect over a billion people worldwide.  
These disorders can be grouped according to iron deficiency, the major cause of 
anemia, and iron overload, the major cause of death in patients with 
hemochromatosis. The past decade has been termed, “The Golden Age in Iron 
Biology”, due to the significant increase in the understanding of the molecular 
underpinnings of systemic iron homeostasis. However, therapeutic options 
remain static.  Anemia is managed with blood transfusions or iron 
supplementation, and hemochromatosis is treated with chelation and 
phlebotomy.  These treatments are effective in many cases, but are often poorly 
tolerated and can take years to improve the quality of life for patients. 
 Hepcidin is an antimicrobial peptide produced in the liver and secreted into 
the bloodstream.  Several seminal studies from the past decade have suggested 
that hepcidin is the master regulator of iron homeostasis.  Hepcidin functions by 
binding to ferroportin-1 (Fpn1), the sole mammalian iron exporter, which induces 
its internalization and degradation.  Fpn1 is highly expressed on the basolateral 
side of duodenal enterocytes, and also on macrophages.  Thus, hepcidin acts to 
restrict iron availability by blocking intestinal iron absorption and release of iron 
from macrophages, which recycle iron from senescent erythrocytes. However, 
data from our lab demonstrate that oxygen signaling is a local effector that 
controls iron homeostasis both upstream and downstream of hepcidin. 
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The present work describes a novel signaling pathway by which intestinal 
iron absorption can be controlled by oxygen signaling.  The hypoxia-inducible 
factor (HIF)-2α is a critical regulator of iron absorption during iron deficiency.  In 
the intestine, HIF-2α directly activates divalent metal transporter 1 (Dmt1), 
duodenal ferric reductase (DcytB), and Fpn1, which are iron transporters critical 
for adaptive changes in iron absorption.  The present work builds on this to show 
that during increased iron demands from erythropoiesis, iron absorption is 
activated in a HIF-2α-dependent manner, and loss of intestinal HIF-2α inhibits 
hematopoietic recovery. In addition, β-thalassemia is a genetic disorder 
characterized by ineffective erythropoiesis causing severe anemia and iron 
overload. Using a mouse model of the disease, this study shows that loss of 
intestinal HIF-2α prevents iron overload.  Together, these data demonstrate that 
intestinal HIF-2α activity is essential for the adaptive changes in iron absorption 
and could be targeted therapeutically to treat anemia and iron overload.   
In addition to the critical role of intestinal HIF-2α in iron homeostasis, liver 
HIF signaling is also a critical regulator of iron homeostasis. Hepcidin is regulated 
by multiple signaling pathways, and one of the least understood regulators of 
hepcidin expression is hypoxia.  The present work demonstrates that hypoxic 
repression of hepcidin requires HIFs and is mediated by a decrease in CCAAT-
enhancer binding protein alpha (C/EBPα) protein in the liver.  Subsequently, this 
work shows that ethanol-mediated hepcidin repression, which exacerbates liver 
injury, requires HIF activity.  Together, these models demonstrate that HIFs are 
	  
	  xii	  
the central regulators of iron homeostasis and can be targeted therapeutically to 









































 Iron is an essential micronutrient found in nearly all forms of life and 
functions as a cofactor for enzymes in a multitude of pathways.  In humans, most 
iron is found as a component of hemoglobin, the oxygen-carrying complex 
present in red blood cells (RBCs).  Thus, iron deficiency leads to anemia, which 
is highly prevalent worldwide.  While iron is essential for the ability of RBCs to 
carry oxygen, it can be harmful when it is present in excess amounts.  To attest 
to this, there are multiple human disorders of iron overload, which can progress 
nearly asymptomatically until organ injury has occurred (1). In this chapter, I will 
first cover general iron homeostasis and focus on mechanisms critical for 
intestinal iron absorption. Following this, I will review the role of hepcidin, which is 
a major regulator of systemic iron homeostasis. Then, I will discuss iron-related 
diseases associated with insufficient or excess hepcidin levels.  Lastly, I will 
cover the novel role of hypoxia signaling in regulating both intestinal iron 
absorption and hepcidin expression. 
 
1.1 Iron homeostasis and intestinal iron absorption 
 Nearly all known living organisms require iron in order to survive.  This is 
due to its role in electron transfer, oxygen binding, and catalysis for enzymatic 
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reactions (2).  However, this inherent versatility is associated with toxicity when 
iron is present in excess amounts, primarily due to its ability to produce hydroxyl 
radicals through the Haber-Weiss-Fenton sequence (3). 
Fe2+ + O2 à Fe3+ + O2-. 
2O2-. + 2H+ à H2O2 + O2 
Fe2+ + H2O2 à OH. + OH- + Fe3+ 
The hydroxyl radical will react with nucleic acids, carbohydrates, and proteins, 
which leads to chain propagating lipid peroxidation (4).  Thus, cellular iron levels 
must be tightly controlled in order to limit iron-mediated damage.  Cellular iron is 
stored in a large, multi-subunit complex called ferritin.  The importance of ferritin 
in iron storage is evidenced by embryonic lethality in ferritin knockout mice (5). 
 While iron is toxic in excess amounts, it is also necessary for cell survival 
and there is a regulated mechanism for cellular iron uptake.  Iron in circulation is 
normally bound to transferrin.  Transferrin is an 80 kDa protein primarily 
produced by the liver (6).  Transferrin binds with high affinity to ferric, but not 
ferrous iron (7).  Circulating iron-loaded transferrin binds to the transferrin 
receptor (Tfr1), which leads to endocytosis of the ligand-receptor complex (8).  
Iron in the endosome is then reduced by the six-transmembrane epithelial 
antigen of prostate 3 (Steap3) metalloreductase (9) before being transported into 
the cytosol by divalent metal transporter 1 (Dmt1) or Zrt- and Irt-like protein 14 
(Zip14) (10, 11). 
 Most iron in the human body is present in hemoglobin contained in RBCs 
and their progenitors (12).  Iron is also present in myoglobin of muscle, 
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macrophages of the reticuloendothelial system, and excess iron is stored in the 
liver (13).  In humans, 20 mg of iron each day is necessary for production of new 
RBCs, and most of this iron is made available by the recycling of senescent 
RBCs by macrophages (14). 1-2 mg of iron is lost each day due to shedding of 
skin and intestinal epithelial cells, which is replaced through intestinal iron 
absorption (15). 
 Iron absorption in the small intestine is a tightly regulated process.  Dietary 
iron, which is primarily in the ferric (Fe3+) form, must first be reduced to ferrous 
iron (Fe2+) by the apical duodenal ferric reductase (DcytB) (16-18).  However, 
DcytB has been shown to be unnecessary for systemic iron homeostasis, 
suggesting that other proteins may compensate for its activity (19, 20).  Dmt1 
then imports ferrous iron into the enterocyte (17, 21, 22).  The central role of 
Dmt1 in iron homeostasis is underscored in mice lacking Dmt1 in the intestine, 
which leads to progressive anemia and decreased survival (23).  Cytosolic iron is 
loaded into the protein ferritin, which serves to compartmentalize iron (24).  In 
order for iron to exit the enterocyte and enter the bloodstream, Fe2+ must first be 
oxidized to Fe3+ by the multicopper ferroxidase hephaestin (25) before exiting 
through the only known mammalian basolateral iron exporter, ferroportin (Fpn1) 
(26-29) (Fig. 1.1A).  The central role of Fpn1 in intestinal iron absorption is 
evidenced in mice lacking intestinal Fpn1, which rapidly succumb to severe 
anemia (30). One of the major mechanisms controlling expression of these 




Regulation by the IRE/IRP system 
 The IRE/IRP system is a complex regulatory network by which intracellular 
iron levels control transcript stability and translation of several proteins involved 
in maintenance of iron homeostasis (31, 32).  See Muckenthaler et al. for a 
comprehensive review of this pathway (33).  Briefly, iron regulatory proteins 1 
and 2 (IRP1 and IRP2) become active under conditions of intracellular iron 
deficiency, which allows IRPs to bind to a hairpin iron-responsive element (IRE) 
present in either the 5’ or 3’ untranslated region (UTR) of target mRNAs (Fig. 
1.2).  Binding of IRP1 or 2 leads to an increase in transcript stability or a block in 
translation.  The major Dmt1 isoform expressed in the duodenum has an IRE in 
its 3’ UTR (34). Mice lacking both IRP1 and IRP2 expression in the intestine have 
a robust decrease in Dmt1, suggesting that the activated IRE/IRP system serves 
to stabilize Dmt1 (34).  Since the IRP proteins are activated by intracellular iron 
deficiency, stabilization of Dmt1 under these conditions serves to bring more iron 
into the enterocyte to correct the deficiency. 
 Iron that enters the cell becomes rapidly trapped in the iron storage 
complex ferritin (24).  Ferritin is composed of heavy and light chains, and both 
subunits are regulated by the IRP system.  When IRP activity is inhibited, the 
ferritin subunits are upregulated (35).  The IRP system serves to decrease ferritin 
translation under conditions of intracellular iron deficiency.  Since ferritin serves 
to sequester and store iron, ferritin downregulation leads to a more readily 
available intracellular iron pool.  Iron exits the enterocyte and enters the 
circulation through the basolateral iron exporter, Fpn1.  The Fpn1 transcript 
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contains a functional IRE in its 5’ UTR, and intracellular iron deficiency leads to 
an IRP-mediated block in Fpn1 translation (36, 37).  This mechanism serves to 
keep intracellular iron levels high, but low intestinal Fpn1 levels during dietary 
iron deficiency causes anemia (37).  However, in the duodenum the major Fpn1 
transcript lacks an IRE, leading to efficient translation under iron-deficient 
conditions where IRPs are active (38).  Therefore, dietary iron deficiency through 
the IRE/IRP system can increase Dmt1 and decrease ferritin to transport in more 
iron, and Fpn1 can evade repression through alternative transcription to export 
iron into the circulation. 
 
*1.2  Regulation of hepcidin 
Hepcidin is a 25 amino acid antimicrobial peptide that is produced in the 
liver and secreted into the bloodstream (39).  Hepcidin is translated as an 84 
amino acid pro-protein, and cleaved by furin to produce the active peptide (40).  
Hepcidin is regulated by a complex network of signaling pathways which will be 
further described in this section (Fig. 1.3).  The role of hepcidin in iron 
homeostasis was first demonstrated in 2001, when upstream transcription factor 
2 (USF2) knockout mice were shown to have decreased hepcidin levels and 
severe iron overload (41).  This is due to the close genomic proximity of the 
USF2 and hepcidin genes, such that both genes were deleted in the USF2 
knockout mice. In a subsequent paper, mice with a specific disruption of 
hepcidin, but having normal USF2 expression, developed severe 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  This section is adapted from a published manuscript:  Anderson ER and Shah 
YM (2013). “Iron homeostasis in the liver.”  Comprehensive Physiology 
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hemochromatosis (42).  Conversely, animals that overexpress hepcidin in the 
liver demonstrate severe iron-deficiency anemia (43).   
A clue to the function of hepcidin was discovered after subjecting rats to 
an iron-deficient diet.  Following iron deficiency, rats rapidly downregulate liver 
hepcidin and upregulate the intestinal iron transporters Dmt1, DcytB, and Fpn1 
(44).  Hepcidin was believed to regulate iron homeostasis due to an interaction 
with iron transporters. A breakthrough occurred when the hepcidin receptor was 
discovered.  Through careful in vitro analysis, it was determined that hepcidin 
binds to Fpn1 which leads to its internalization and proteasomal degradation 
(45).  With the connection between hepcidin and Fpn1 solidified, its role in iron 
homeostasis became clear.  Hepcidin is increased in iron loading, which leads to 
limitation of duodenal iron absorption to normalize iron levels.  In the case of iron 
deficiency anemia, hepcidin is repressed and Fpn1 is stabilized, which increases 
iron export from the enterocyte.  In addition, Fpn1 is increased in macrophages 
following erythrophagocytosis, and hepcidin is able to lead to Fpn1 degradation 
in these cells (46).  Thus, hepcidin was determined to be the master regulator of 
both duodenal iron absorption and RBC iron recycling.   
One major discovery in the regulation of hepcidin was the involvement of 
SMAD family member 4 (SMAD4).  Liver-specific knockout of SMAD4 leads to 
near abolition of hepcidin expression (47).  These mice die of severe iron 
overload in multiple tissues. Liver SMAD4 knockout mice are unable to increase 
hepcidin expression in response to iron loading, suggesting that SMAD4 
mediates the response of hepcidin to systemic iron requirements.  It was 
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subsequently shown that bone morphogenetic protein (BMP), but not 
transforming growth factor beta 1 (TGF-β) signaling, both of which function 
through SMADs, induced hepcidin expression in cultured liver cell lines and in 
vivo (48).  It is known that signaling through the BMP receptor leads to 
SMAD1/5/8 phosphorylation, which is required for SMAD4 transcriptional activity 
(49). In times of increased systemic requirements for iron, phosphorylated 
SMAD1/5/8 drops dramatically, and it is substantially increased in conditions of 
iron overload.  However, the precise molecular mechanisms for how hepcidin is 
regulated by iron remain unclear.  Studying mutations identified in iron-related 
disorders provided further insight into how BMP/SMAD signaling modulates 
hepcidin expression. The significance of these mutations and the proteins they 
encode will be discussed in more detail below.  
 In addition to iron, increased production of RBCs also modulates hepcidin 
expression. In a phenylhydrazine (PhZ)-induced hemolytic anemia model, 
which induces erythropoiesis, duodenal iron absorption is increased following a 
decrease in hepcidin expression (50).  In addition, phlebotomy, or repeated 
bleeding also causes hepcidin repression (51).  The mechanism was further 
delineated demonstrating that treatments such as PhZ and phlebotomy could 
only decrease hepcidin expression in situations where erythropoiesis can 
proceed (52). Several mechanisms have been attributed to erythropoietic 




*1.3  Iron related disorders 
Anemia 
 Anemia is defined as a decrease in RBCs or abnormally low hemoglobin 
levels.  One common cause of anemia is iron deficiency, which is especially 
prevalent in children and pregnant women (55).  Maternal iron supplementation is 
effective in reducing anemia and incidence of low birth weights (55).  However, 
iron deficiency anemia is also common in infants that are breastfed, particularly 
in developing countries (56, 57).  In addition, iron is important in early 
psychomotor and cognitive development, increasing the negative impact of iron 
deficiency in young children (58).  While iron supplementation is highly effective 
in combating anemia, distribution of iron supplements is poor in developing 
countries (59). Moreover, in iron-refractory iron deficiency anemia (IRIDA) iron 
supplements are not effective (60). Studying this disease has shed light on novel 
mediators of hepcidin expression. Patients with IRIDA have high hepcidin 
expression, which is the primary cause leading to anemia and non-
responsiveness to iron supplementation.  
 Recently, mutations in transmembrane protease serine 6 (TMPRSS6), 
which encodes a type II transmembrane serine protease (matriptase-2), were 
identified in patients with IRIDA.  This was confirmed in the mouse TMPRSS6 
knockout, which had hair loss and microcytic anemia associated with high levels 
of hepcidin expression (61, 62).  As discussed above, BMP signaling is essential 
for hepcidin expression (Section 1.2), and the connection between TMPRSS6 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  This section is adapted from a published manuscript:  Anderson ER and Shah 
YM (2013). “Iron homeostasis in the liver.”  Comprehensive Physiology	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and BMP signaling was made with the discovery that matriptase-2 cleaves 
membrane hemojuvelin (Hjv). Hjv is a BMP6 co-receptor. Functional matriptase-2 
restricts hepcidin expression by cleaving Hjv. However, the mutated form found 
in IRIDA cannot cleave Hjv, which leads to increased expression of hepcidin and 
iron deficiency (63). 
 One highly prevalent disorder of anemia is the anemia of chronic disease, 
which encompasses several diseases including kidney disease, inflammatory 
disease, cancer, and aging (64). In healthy human volunteers and mice, studies 
demonstrate that inflammatory agents cause a robust and rapid decrease in 
serum iron levels (65-68). Hepcidin is induced in response to inflammatory stimuli 
(69-71).  The mechanism for the induction of hepcidin by inflammation is 
mediated by interleukin-6 (IL-6)-induced signal transducer and activator of 
transcription 3 (STAT3) activity, which increases hepcidin expression in cultured 
cells, mice, and humans (67, 72-74) (Figure 1.3). The increase in hepcdin is 
thought to be a protective mechanism that restricts iron to infectious pathogens. 
However, in chronic disorders this leads to anemia, which can have detrimental 
effects in the primary disease pathogenesis.  Similarly, in most cancers there is a 
decrease in serum iron levels and increased anemia (75).  The best treatment for 
anemia of chronic disease is resolving the primary chronic disease. In severe 
cases blood transfusion, erythropoietin (EPO), or intravenous administration of 
iron is used (76).  
 
Iron overload  
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 Iron overload diseases are characterized by pathological iron 
accumulation and can be caused by a wide variety of genetic factors.  One very 
common cause of iron overload is hereditary hemochromatosis (HH), which is a 
genetic disorder that affects 1 in 200 people (77).  The most common mutation 
observed in HH is in HFE. The Hfe gene encodes an atypical major 
histocompatibility complex protein, and the C282Y mutation is the most common 
cause of HH in humans (78, 79).  Mice with either a deletion of Hfe or a knock-in 
C282Y allele demonstrate iron overload which is associated with decreased 
hepcidin expression (80).  HFE is expressed in many tissues important for iron 
homeostasis, including the liver and intestine.  Conditional disruption of HFE in 
the liver, but not intestine, recapitulates the iron overload phenotype, 
demonstrating that the primary role of HFE is to regulate hepcidin expression in 
the liver (81, 82).  It is thought that HFE controls hepcidin expression in iron-
loaded conditions, and lack of HFE leads to a blunted increase in hepcidin 
expression during iron overload (83).  
Juvenile hemochromatosis (JH) is a rare autosomal recessive disorder of 
iron overload and symptoms become apparent before the age of 30.  JH is 
caused by mutations in the gene for Hfe2, which encodes for Hjv (84), the BMP6 
coreceptor, as discussed above in more detail. The Hjv knockout mouse model 
demonstrates severe iron overload associated with a dramatic decrease in 
hepcidin expression, similar to that observed in patients with Hjv mutations (84, 
85).  Similar to Hjv mutations, mutations in the hepcidin antimicrobial peptide 
(Hamp) gene, which encodes for hepcidin, are a very rare cause of JH. Currently 
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12 known mutations occur on the Hamp gene leading to a decrease in the 
normal production of hepcidin (86).  Since hepcidin function or expression is 
dramatically diminished, the iron overload symptoms are observed before the 
age of 30. 
Transferrin receptor 2 (Tfr2) mutations lead to an autosomal recessive iron 
overload disease similar to the HFE-related HH phenotype. Tfr2 is capable of 
binding to HFE and this interaction is critical in maintaining hepcidin expression 
(87).  The knockout mouse model and the liver-specific disruption of Tfr2 confirm 
its importance in regulating hepcidin levels (88).  Hepcidin levels are decreased 
significantly in these mouse models compared to littermate controls, and tissue 
iron is increased. 
 If left untreated, hemochromatosis causes liver cirrhosis, cardiomyopathy, 
diabetes, and arthritis (79).  The most common form of treatment is therapeutic 
phlebotomy, which is effective in decreasing iron but is complicated by poor 
compliance with treatment and is contraindicated in patients with anemia and 
other diseases (89).  Another treatment option is oral iron chelation using 
deferasirox, which also reduces iron levels but is associated with the side effects 
of diarrhea, headache, and nausea (90).  
 
Thalassemia 
 In addition to hereditary hemochromatosis, there exist diseases of 
secondary hemochromatosis such as β-thalassemia in which iron overload is a 
complication of the primary disorder. β-thalassemia is a genetic disorder in which 
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the β-globin gene is partially or completely deleted, which leads to β-thalassemia 
intermedia and Cooley’s anemia, respectively (91).  Patients with β-thalassemia 
demonstrate anemia that is controlled with blood transfusions when necessary.  
Blood transfusions, however, constitute a major source of iron which contributes 
to the pathological consequence of iron overload in thalassemic patients (92).  
Interestingly, iron overload and its pathological consequences are prevalent in 
patients who do not receive regular transfusions, suggesting that increased iron 
absorption could contribute to iron overload in β-thalassemia (93).  Indeed, 
mouse models of the disease demonstrate increased iron absorption that is 
accompanied by a decrease in hepcidin expression (94). 
 Since hepcidin is a major regulator of iron homeostasis, much work has 
gone into investigating the role of hepcidin in the pathogenesis of β-thalassemia 
(95).  Growth-differentiation factor 15 (GDF15) and twisted gastrulation (TWSG1) 
are two factors produced by erythroid cells that are correlated to decreases in 
hepcidin expression in thalassemia (53, 54).  However, recent data demonstrate 
that neither GDF15 nor TWSG1 are likely to be involved in the suppression of 
hepcidin expression during erythropoiesis (96).  More recently we have shown 
that suppression of BMP/SMAD signaling is important for hepcidin repression in 
β-thalassemia (97).  The mechanism of hepcidin repression in β-thalassemia 
remains incompletely understood.  However, the potential of hepcidin as a 
treatment tool for iron overload disorders is clear.  Deletion of TMPRSS6, which 
leads to increased hepcidin expression, substantially ameliorates iron overload 
and anemia in β-thalassemia (98).  In addition, transgenic overexpression of 
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hepcidin in the liver also improves the disease (99).  However, alternative 
therapeutic strategies are sought due to the ability of hepcidin to induce anemia 
(43). 
  
1.4  Regulation of iron homeostasis by hypoxia signaling 
  In addition to regulation of iron absorption by hepcidin and the IRE/IRP 
system, there are also mechanisms that induce intestinal iron transporters at the 
transcriptional level.  In multiple mouse strains, the duodenal iron transporters 
Dmt1, DcytB, and Fpn1 are induced during dietary iron deficiency (100).  
Subsequent work shows that oxygen signaling is essential for intestinal iron 
transporter gene expression.  Oxygen signaling is primarily controlled by a family 
of hypoxia-inducible transcription factors (HIFs).  The HIF complex consists of a 
constitutively present HIF-β subunit, also known as aryl hydrocarbon receptor 
nuclear translocator (ARNT), and an oxygen-regulated HIF-α subunit (101).  
Under normal oxygen and iron levels, the HIF-α subunit is hydroxylated by a 
family of prolyl hydroxylases, and this allows the von Hippel-Lindau tumor 
suppressor (VHL) to bind HIF-α and promote its ubiquitination and proteasomal 
degradation (102) (Fig. 1.4). 
 HIF-2α specifically is essential for the induction of the iron absorption 
genes Dmt1, DcytB, and Fpn1 in response to an iron-deficient diet (103, 104) 
(Fig. 1.1B).  Through promoter luciferase and chromatin immunoprecipitation 
assays, all three genes have been demonstrated to be direct HIF-2α targets 
(103-105).  Expression of these iron transporters in the intestine is induced 
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during erythropoietic stress, although the mechanism remained unclear until our 
recent work (106). In addition to dietary iron deficiency and erythropoiesis, HIF-
2α is necessary for iron absorption in hepcidin knockout mice, a model of iron 
overload (107). 
At the beginning of my work, hepcidin was widely accepted to be the 
primary regulator of iron homeostasis under all pathological and physiological 
conditions.  My thesis builds upon and expands the observation that intestinal 
HIF-2α is an important local regulator of iron absorption during iron deficiency 
(103).  Moreover, HIF-2α is essential in iron absorption to meet systemic iron 
needs during erythropoietic stress (106). Chapter 2 of this thesis examines the 
role of intestinal HIF-2α during erythropoietic iron absorption. 
Increased iron absorption in β-thalassemia is attributed to a decrease in 
hepcidin expression (94), but the role of intestinal HIF-2α in this disease has not 
been examined.  Chapter 3 of this thesis demonstrates that intestinal HIF-2α is 
essential for iron overload in β-thalassemia, calling into question the dominant 
role hepcidin is purported to play in the disease.  Furthermore, loss of intestinal 
HIF-2α allows rapid mobilization of iron stores in response to erythropoietic 
stress, suggesting that intestinal HIF-2α could be a therapeutic target in disorders 
of iron overload. 
 In addition to hypoxic regulation of local iron absorption in the intestine, 
hypoxia is important in systemic iron regulation as well. Hypoxia strongly 
represses hepcidin expression both in cultured cells and in mice (108).  
Moreover, a human mutation that leads to HIF stabilization, Chuvash 
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polycythemia, causes decreased hepcidin levels without a significant association 
with erythropoiesis (109). Many mechanisms have been proposed to play a role 
in hypoxic hepcidin repression (110-117) (Figure 1.3). However, the mechanism 
for hypoxic regulation of hepcidin is still unclear. In Chapter 4 we demonstrate 
that HIFs regulate hepcidin expression by decreasing the expression of 
CCAAT/enhancer binding protein alpha (C/EBPα), which is required for basal 
hepcidin expression. Moreover, patients with alcoholic liver disease (ALD) have 
liver iron accumulation (118). Chapter 4 of this thesis also shows that hypoxia is 
the major regulator of hepcidin expression during ethanol consumption (119). 
 The work presented in this thesis strongly challenges the dominant role of 
hepcidin in controlling systemic iron homeostasis, and proposes that HIF 
signaling plays an essential role in the maintenance of iron homeostasis.  
Intestinal HIF-2α, not hepcidin, is responsible for increased iron absorption during 
erythropoiesis. Moreover, iron overload in β-thalassemia is abolished with loss of 
intestinal HIF-2α, despite an intact hepcidin response. Lastly, HIF signaling plays 
a critical role in modulating hepcidin expression during ethanol consumption, with 
implications for iron overload in ALD. Thus, activation or inhibition of HIF 
signaling in the liver or intestine could be used therapeutically to control systemic 







          Normal Iron diet                    Dietary iron deficiency 
 
Figure 1.1.  Regulation of intestinal iron transport.  A) Luminal iron, primarily 
in ferric form (Fe3+) is reduced by the duodenal ferric reductase DcytB.  Ferrous 
(Fe2+) iron is transported into the enterocyte the divalent metal transporter-1 
(DMT1).  Intracellular iron is stored in the ferritin complex or exported through the 
only basolateral iron exporter, ferroportin (FPN).  B) Under conditions of dietary 
iron deficiency, intestinal HIF-2α is stabilized, leading to increased transcription 
of its target genes Dmt1, DcytB, and Fpn.  This leads to increased apical iron 
absorption and basolateral iron transfer.  [Reproduced with permission from 




Figure 1.2.  Control of iron homeostasis by iron regulatory proteins (IRPs).  
Under conditions of iron repletion, the IRP proteins are inactivated, leading to 
decreased stability of the iron importer Dmt1, and increased stability of the iron 
exporter Fpn1 and the iron storage protein ferritin.  Under conditions of low iron, 
the IRP proteins become active and bind to a hairpin in the 5’ or 3’ UTR of target 
mRNAs.  This increases stability of Dmt1 mRNA and decreases translation of 
Fpn1 and ferritin mRNA, resulting in an increased level of cellular iron to 




Figure 1.3.  Regulation of hepcidin expression.  Transferrin/transferrin 
receptor interactions and Bmp signaling lead to increased SMAD1/5/8 
phosphorylation, which is required for SMAD4 activation of the hepcidin 
promoter.  The inflammatory cytokine IL-6 binds to its receptor, leading to STAT3 
phosphorylation and promoter activation.  Hypoxia represses hepcidin through 
stimulation of erythropoiesis, which is mediated by an erythroid factor, removal of 
C/EBPα from the hepcidin promoter, and direct HIF binding to the hepcidin 







Figure 1.4.  Regulation of HIF activity.  Under conditions of normal oxygen and 
iron levels, prolyl hydroxylase domain enzymes (PHD) hydroxylate specific 
proline residues on the HIFα protein allowing VHL to bind, which leads to 
polyubiquitination and proteasomal degradation of HIFα.  Under conditions of iron 
or oxygen deficiency, PHD activity is inhibited and HIFα is not hydroxylated.  This 
prevents VHL binding, which allows HIFα to become stabilized, translocate to the 
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Intestinal Hypoxia-inducible Factor-2α is Critical for Efficient 
Erythropoiesis* 
Abstract: 
 Erythropoiesis is a coordinated process by which RBCs are produced. 
Erythropoietin, a kidney-derived hormone, and iron are critical for the production 
of oxygen-carrying mature RBCs. To meet the high demands of iron during 
erythropoiesis, small intestinal iron absorption is increased through an undefined 
mechanism. In this study, erythropoietic induction of iron absorption was further 
investigated. Hypoxia-inducible factor-2α (HIF-2α) signaling was activated in the 
small intestine during erythropoiesis. Genetic disruption of HIF-2α in the intestine 
abolished the increase in iron absorption genes as assessed by quantitative real-
time reverse transcription-PCR and Western blot analyses. Moreover, the 
increase in serum iron following induction of erythropoiesis was entirely 
dependent on intestinal HIF-2α expression. Complete blood count analysis 
demonstrated that disruption of intestinal HIF-2α inhibited efficient erythropoiesis; 
mice disrupted for HIF-2α demonstrated lower hematocrit, RBCs, and Hb 
compared with wild-type mice. These data further cement the essential role of 
HIF-2α in regulating iron absorption and also demonstrate that hypoxia sensing
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in the intestine, as well as in the kidney, is essential for regulation of 
erythropoiesis by HIF-2α. 
 
Introduction 
 Erythropoiesis is a tightly regulated process involved in maintaining and 
modulating RBC production under both normal and pathological conditions. 
Erythropoiesis is controlled by erythropoietin (EPO), which is produced by the 
kidney and secreted into the bloodstream (1).  EPO acts on red blood cell 
progenitors in the bone marrow to stimulate their differentiation (2).  When large 
numbers of erythrocytes are lost due to disease or injury, EPO production 
increases dramatically, leading to increased erythrocyte production to restore the 
RBC population (3).  Increased erythrocyte production requires an increase in 
available iron to produce Hb (4).  Erythropoiesis stimulates expression of iron 
absorption genes in the small intestine, although the mechanism by which this 
occurs is unknown (5-7).  Erythropoiesis-stimulating agents are commonly used 
to increase serum iron levels to combat iron deficiency anemia, particularly in 
cancer patients and patients with chronic kidney disease (8). 
 In addition, β-thalassemia is a common genetic disorder caused by 
mutations in the β-globin gene, which result in ineffective erythropoiesis leading 
to iron overload (9).  In β-thalassemia patients, intestinal iron absorption is three 
to four times greater than in normal control patients, and the increase in 




Intestinal iron absorption is tightly regulated by the small intestine. Dietary 
iron is primarily in ferric (Fe3+) form and is reduced to ferrous (Fe2+) iron by the 
duodenal ferric reductase (DcytB) (11-13).  Ferrous iron is then transported into 
the enterocyte by Dmt1 (divalent metal transporter 1) (12, 14, 15).  To enter 
circulation, ferrous iron passes through the only characterized basolateral iron 
exporter, Fpn1 (ferroportin-1) (16-19).  Hepcidin, a liver-derived peptide that 
regulates iron homeostasis through Fpn1 degradation (20-22), has been 
implicated in the increase in iron absorption following erythropoiesis and in 
thalassemia patients (10, 23-25).  However, other mechanisms that regulate 
intestinal iron absorption are thought to be involved because hepcidin expression 
does not completely ameliorate the iron overload in β-thalassemic mouse models 
(23), and the effect of hepcidin on intestinal iron absorption does not appear to 
be direct and rapid (26-30). 
 In addition to hepcidin, the transcription factor hypoxia-inducible factor-2α 
(HIF-2α) is necessary for intestinal iron absorption following iron deficiency (31, 
32).  HIF-2α is a heterodimeric transcription factor consisting of an iron- and 
oxygen-regulated α-subunit and a constitutively expressed β-subunit, the aryl 
hydrocarbon receptor nuclear translocator (also known as HIF-β) (33).  Under 
normal cellular oxygen and iron levels, HIF-2α is hydroxylated at specific proline 
residues, which are required for Von Hippel-Lindau (VHL) tumor suppressor 
binding. VHL is the substrate recognition portion of an E3 ubiquitin ligase 
complex and is necessary for ubiquitination and subsequent proteasomal 
degradation of HIF-2α. The prolyl hydroxylases responsible for hydroxylation of
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HIF-2α require oxygen and iron as cofactors (34).  During iron deficiency, prolyl 
hydroxylase activity is inhibited, and HIF-2α accumulates, dimerizes with the aryl 
hydrocarbon receptor nuclear translocator, and activates transcription of its target 
genes. HIF-2α binds to consensus hypoxia response elements in the promoters 
of genes involved in maintaining iron homeostasis, such as Dcytb, Dmt1, and 
Fpn1 (27, 31, 32).  Because HIF-2α is critical in maintaining iron homeostasis 
following iron deficiency, in this study, we assessed whether similar mechanisms 
are required for the erythropoietic induction of iron absorption genes in the small 
intestine.  Wild-type and intestinal HIF-2α knock-out mice were administered 
phenylhydrazine (PhZ), which causes hemolysis and stimulates erythropoiesis 
(5-7).  It is shown that intestinal HIF-2α is critical not only for the erythropoietic 
induction of iron absorption genes in the small intestine but also for the increase 
in serum iron, which in turn is necessary for efficient erythropoiesis. 
 
Experimental Procedures 
Animals and Treatments 
 VhlF/F (35), VhlΔIE (36), Hif-2αF/F, and Hif-2αΔIE (27) mice were described 
previously. The mice were housed in a light- and temperature-controlled room 
and were given water and chow ad libitum. PhZ (Sigma) was dissolved in 
neutralized saline. Mice were injected at 60 mg/kg of body weight on 2 
consecutive days and were killed 2, 3, and 7 days following the second injection. 
Tissues were harvested and used fresh or flash-frozen in liquid nitrogen and 
stored at −80 °C for future use. All animal studies were carried out in accordance 
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with Institute of Laboratory Animal Resources guidelines and approved by the 
University Committee on the Use and Care of Animals at the University of 
Michigan. 
Western Blot Analysis 
 Tissues were homogenized and lysed in radio immune precipitation assay 
buffer for whole cell extracts, and nuclear proteins were isolated using the NE-
PER nuclear extraction kit (Pierce). Membrane proteins were isolated as 
described previously (27).  Membrane extracts were incubated for 5 min at 65 °C 
for detection of DcytB, whereas all other extracts were heated at 95 °C for 5 min. 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes using standard methods. Membranes were incubated with 
antibodies against HIF-1α and HIF-2α (Novus Biologicals, Littleton, CO), Dmt1 
and DcytB (Alpha Diagnostic International Inc., San Antonio, TX), and RAN 
(Santa Cruz Biotechnology, Santa Cruz, CA). For in vivo hypoxia detection, 
nitroimidazole was dissolved in normal saline with 2.4% ethanol and injected at 
200 mg/kg of body weight 90 min before harvesting tissues. The signal was 
measured by using an antibody to nitroimidazole-protein adducts (HPI Inc., 
Burlington, MA) in whole cell extracts. 
Quantitative Real-time Reverse Transcription-PCR (qPCR) 
 RNA was isolated from fresh or frozen tissue using Isol-RNA lysis reagent 
(5 PRIME, Gaithersburg, MD) and reverse-transcribed using Moloney murine 
leukemia virus reverse transcriptase (Fisher). cDNA was quantified using SYBR 
Green dye and run on a 7900HT fast real-time PCR system (primers are listed in 
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Table 2.1).  Ct values were normalized to β-actin and expressed as -fold 
difference from controls. 
Iron and Hematological Analysis 
 Serum iron was analyzed using the QuantiChrom iron assay kit (Bioassay 
Systems, Hayward, CA) following the manufacturer's protocol. Tissue iron in 
small intestinal epithelium was measured as described previously (37).  Briefly, 
tissues were digested in 3 M HCl and 10% trichloroacetic acid at 65 °C for 20 h 
and then compared against an iron standard by a colorimetric assay. Complete 
blood count analysis was performed by the Unit for Laboratory Animal Medicine 
Pathology Core for Animal Research. 
Immunohistochemistry 
 Duodenums were Swiss-rolled, frozen in cryo-embedding medium, and 
sectioned at 7 µm. The sections were fixed in 4% paraformaldehyde in PBS and 
incubated overnight at 4 °C with rabbit anti-mouse Fpn1 antibody (1:100; Alpha 
Diagnostic International Inc.) diluted in PBS with 2% BSA. Slides were washed 
twice with PBS and then incubated for 1 h at room temperature with Alexa Fluor® 
488-labeled goat anti-rabbit IgG (1:500; Molecular Probes, Inc., Eugene, OR) 
diluted in PBS with 2% BSA. After incubation with the secondary antibody, all 
sections were washed three times for 5 min with PBS and mounted with 
ProLong® gold antifade reagent with DAPI (Molecular Probes, Inc.). 
Immunofluorescence was visualized using a Nikon Eclipse TE200 microscope 
with a ×20 objective. Images were acquired using an Olympus DP71 microscope 
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digital camera and processed using an Olympus DP Controller Version 3.2.1.276 
software package (Olympus America Inc., Center Valley, PA). 
Cell Culture 
 Caco-2 cells were maintained at 37 °C in 5% CO2 and 21% O2. Cells were 
cultured in DMEM supplemented with 10% FBS and 1% antibiotic/antimycotic. 
For EPO experiments, cells were switched to serum-free medium 24 h before 
EPO incubation. Recombinant human erythropoietin (Prospec, East Brunswick, 
NJ) was used at a concentration of 10 or 100 IU/ml, and cells were incubated for 
24 h. Cells were lysed in radioimmune precipitation assay buffer, and Western 
blot analysis was performed. For hypoxia experiments, cells were incubated in 
1% O2 and 5% CO2 with balance N2 at 37 °C for 24 h. 
 
Results 
PhZ Treatment Induces Expression of Epo in the Kidney and Iron Absorption 
Genes in the Small Intestine 
 PhZ is commonly used to study hemolytic anemia-induced erythropoiesis 
(5-7, 26).  A dramatic decrease in RBCs following PhZ treatment leads to 
hypoxia in the kidney (1).  This stabilizes HIF-2, activating EPO expression (1), 
and stimulates RBC differentiation and maturation into erythrocytes (2).  Wild-
type mice were treated with PhZ for 2 consecutive days and killed 48 h following 
final treatment. Epo mRNA expression was highly induced in the kidney, but not 
in the liver. Also, liver hepcidin mRNA expression was strongly suppressed (Fig. 
2.1A), consistent with a previous report (25).  Expression of Dmt1a and Dcytb 
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was significantly increased in the duodenums of treated mice compared with 
untreated controls as assessed by qPCR. Fpn1 expression was not affected, 
however (Fig. 2.1B).  Because erythropoiesis increases the demand for iron, 
these integrative changes provide an efficient system to increase the available 
iron stores. Moreover, PhZ treatment provides an ideal model to assess the 
mechanism by which iron absorption is induced following erythropoiesis. 
Erythropoietic Induction of Iron Absorption Genes in the Small Intestine is HIF-
2α-dependent 
 Chronic low iron treatment induces the expression of iron absorption 
genes in the small intestine through a HIF-2α-dependent mechanism (27, 31, 
32).  However, the precise molecular mechanisms by which iron absorption is 
increased to satisfy systemic iron requirements during erythropoiesis are 
unknown. To investigate whether HIF-2α is also critical in erythropoietic induction 
of iron absorption, mice with an intestinal disruption of HIF-2α (Hif-2αΔIE) and 
wild-type littermate controls (Hif-2αF/F) were assessed following PhZ treatment. 
Hif-2αΔIE and Hif-2αF/F mice were treated with PhZ for 2 days and then killed 2 or 
3 days post-treatment. In Hif-2αF/F mice, PhZ increased iron absorption genes in 
the duodenum as assessed by qPCR. However, PhZ induction of intestinal 
Dmt1a and Dcytb was completely abolished in the Hif-2αΔIE mice (Fig. 2.2A).  
Kidney Epo expression was highly induced to the same extent in Hif-2αΔIE mice 
and wild-type littermates, demonstrating that these changes are not due to 
dysregulation of kidney Epo expression (Fig. 2.2B).  Western blotting was 
performed on protein extracts from the duodenum. In Hif-2αF/F mice, DcytB and 
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Dmt1 expression was strongly induced in membrane duodenal extracts 2 and 3 
days post-PhZ treatment. Consistent with the mRNA data, in Hif-2αΔIE mice, 
there was no increase in either Dmt1 or DcytB protein expression following PhZ 
treatment (Fig. 2.2C).  Because Fpn1 expression was not detected by Western 
blotting consistently after PhZ treatment (data not shown), a highly sensitive 
immunohistochemistry assay was performed using intestines from PhZ-treated 
wild-type and Hif-2αΔIE mice. Fpn1 expression was similar following PhZ 
administration in Hif-2αΔIE mice compared with Hif-2αF/F mice, consistent with 
qPCR data (Fig. 2.2D).  These data demonstrate that the induction of the apical 
iron absorption genes in the small intestine is dependent on HIF-2α expression. 
Erythropoiesis Stabilizes HIF-2α, but Not HIF-1α 
 The gene expression data strongly suggest that HIF-2α is necessary for 
PhZ-induced expression of intestinal iron absorption genes. Consistent with 
these data, Western blotting of nuclear extracts prepared from the duodenums of 
PhZ-treated and untreated wild-type mice demonstrated a robust induction of 
HIF-2α, whereas expression of HIF-1α was not detected in duodenal nuclear 
extracts from PhZ-treated mice (Fig. 2.3A).  Intestinal HIF-2α is rapidly stabilized 
by iron deficiency (27, 31, 32); therefore, the possibility that a decrease in 
duodenal iron stabilizes HIF-2α was assessed. Non-heme iron was extracted 
from PhZ-treated and untreated duodenal epithelia and quantified (Fig. 2.3B).  
No significant difference was detected, demonstrating that a decrease in tissue 
iron is not responsible for HIF-2α stabilization following PhZ treatment. 
Intestinal Hypoxia Stabilizes HIF-2α following PhZ-induced Erythropoiesis 
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 Hif-2α has recently been identified as a direct STAT5 target gene in 
hematopoietic stem cells (38).  EPO is a known activator of the JAK2/STAT5 
signaling cascade (39), and therefore, Hif-2α mRNA was assessed. No 
significant increase was detected in duodenal epithelial cells from PhZ-treated 
and untreated wild-type mice (Fig. 2.4A).  Although Hif-2α mRNA was 
unchanged, EPO stabilization of HIF-2α protein was assessed. Caco-2 cells, a 
human colon cancer cell line, were incubated for 24 h in the presence or absence 
of recombinant human EPO. No change in HIF-2α expression was observed 
following EPO incubation (Fig. 2.4B).  In addition, we assessed whether EPO 
and hypoxia could synergistically stabilize HIF-2α. Hypoxia strongly stabilized 
HIF-2α in Caco-2 cells. However, EPO incubation did not potentiate the increase 
in HIF-2α protein expression (Fig. 2.4B).  Moreover, acute treatment of EPO (2, 
4, and 8 h) in Caco-2 cells was performed, and EPO did not alter HIF-2α 
expression at any time points that were assessed (data not shown). These data 
clearly establish that circulating EPO is not involved in intestinal HIF-2α 
expression. An initiating event in erythropoiesis is kidney hypoxia stimulating Epo 
expression in a HIF-2α-dependent manner (40, 41).  Therefore, the possibility 
that oxygen sensing in the small intestine is responsible for HIF-2α stabilization 
was evaluated. The hypoxia-detecting reagent nitroimidazole was used to 
investigate tissue hypoxia. Nitroimidazole forms protein adducts only in tissues 
with low oxygen tension but will not bind to proteins under normoxic conditions 
(42, 43).  It was shown recently that Western blotting performed on extracts from 
cells treated with nitroimidazole is a sensitive and quantitative method for 
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measuring hypoxic adduct formation (44).  Wild-type mice were treated with PhZ 
for 2 days and injected with nitroimidazole 90 min prior to tissue collection. 
Nitroimidazole-protein adducts were detected by Western blotting in PhZ-treated 
and control duodenums, whereas no signal was detected in the oxygen-replete 
lung. In the duodenum, nitroimidazole staining was significantly stronger in the 
PhZ-treated mice compared with the control mice (Fig. 2.4C).  These data 
suggest that following PhZ treatment, HIF-2, but not HIF-1, is stabilized in the 
intestine by hypoxia, a distinct mechanism from HIF-2α stabilization during iron 
deficiency. 
Intestinal HIF-2α Is Necessary for the Erythropoietic Increase in Serum Iron 
 To determine whether HIF-2α-dependent regulation of iron absorption 
genes is required for the increase in systemic iron levels during erythropoiesis, 
serum iron was assessed in control and PhZ-treated wild-type and Hif-2αΔIE 
mice. No significant difference in basal serum iron levels was observed in Hif-
2αΔIE mice compared with wild-type mice. At 2 days post-PhZ treatment, serum 
iron levels were significantly increased in wild-type mice, and the adaptive 
increase in serum iron following PhZ treatment was completely abolished in Hif-
2αΔIE mice. At 7 days post-PhZ treatment, serum iron levels were back to normal 
in wild-type mice (Fig. 2.5).  These data demonstrate that erythropoietic induction 
of iron absorption is dependent on HIF-2α. 
Intestinal HIF-2α Expression Is Required for Efficient Erythropoiesis 
 The erythropoietic induction of iron absorption is completely abolished in 
Hif-2αΔIE mice; therefore, these mice provide an ideal model to assess the 
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significance of intestinal HIF-2α and iron absorption in erythropoiesis. To observe 
how inhibition of iron absorption in Hif-2αΔIE mice could affect erythropoiesis, 
complete blood count analysis was performed on Hif-2αF/F and Hif-2αΔIE mice 
treated with PhZ. Whole blood was taken 2 and 7 days following PhZ treatment. 
Control Hif-2αF/F and Hif-2αΔIE mice had normal RBC, hematocrit (HCT), and Hb 
levels (Fig. 2.6, A-C).  Two days following PhZ treatment, RBC and HCT levels 
decreased significantly in both Hif-2αF/F and Hif-2αΔIE mice, and Hb levels were 
increased. At 7 days post-PhZ treatment, HCT and Hb levels were completely 
recovered in wild-type mice, and RBCs were increased compared with 2 days 
post-treatment. However, Hif-2αΔIE mice demonstrated significantly reduced 
RBC, HCT, and Hb levels compared with wild-type littermates. The changes 
observed in RBCs, HCT, and Hb in the Hif-2αΔIE mice reflect a critical role of 
intestinal HIF-2α in erythropoiesis. 
 
Discussion 
 The induction of iron absorption genes in the intestine by erythropoiesis 
has been described previously, but a mechanism had not been provided prior to 
this study (5-7).  Similar to iron absorption induced by iron deficiency, HIF-2α is a 
critical regulator of iron absorption during erythropoiesis (31, 32).  Intestinal HIF-
2α signaling is essential for the increase in serum iron following induction of 
erythropoiesis by PhZ treatment. Furthermore, the increase in serum iron 
mediated by HIF-2α is essential for erythropoiesis, as it is severely inhibited in 
Hif-2αΔIE mice compared with Hif-2αF/F mice. The results of this study and of 
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previous work demonstrate a central role of HIF-2α in erythropoiesis. Together, 
these data provide a working model for the induction of erythropoiesis (Fig. 2.7).  
A decrease in RBCs results in hypoxic kidneys due to decreased delivery of 
oxygen, which activates HIF-2α expression and subsequently Epo mRNA (40).  
The decrease in RBCs stabilizes intestinal HIF-2α, which activates iron 
absorption genes, leading to an increase in serum iron. Activation of HIF-2α 
signaling in the kidney and intestine is required for efficient RBC synthesis. 
Moreover, EPO acts on the bone marrow to stimulate erythrocyte differentiation 
and maturation, and the renewal of bone marrow-derived hematopoietic stem 
cells is also activated in a HIF-2α-dependent pathway (38). 
 One finding of note is that basal erythropoiesis appears to be largely 
unaffected in Hif-2αΔIE mice compared with Hif-2αF/F mice under control 
conditions. Following erythropoietic stress, hematologic parameters are 
significantly different between Hif-2αΔIE and Hif-2αF/F mice, albeit the changes are 
moderate. Given the essential role of HIF-2α in intestinal iron absorption, one 
might expect a dramatic difference in RBCs, Hb, and HCT in basal as well as 
stress-induced erythropoiesis. One explanation is that a grain-based laboratory 
diet contains 350 ppm of ferrous iron, which is 10-fold higher than the normal 
dietary intake of mice. Moreover, ferrous iron does not require ferric reductase 
activity to be absorbed in the duodenum. It is possible that a diet consisting of 
ferric iron, which makes up the majority of normal dietary iron intake, would lead 
to more striking changes in hematologic parameters in Hif-2αΔIE mice. 
	  
	  43	  
 Fpn1 is up-regulated in a HIF-2α-dependent manner following low iron 
treatment (27).  However, HIF-2α activation following PhZ treatment did not 
increase Fpn1 expression. Also, an increase in Fpn1 does not appear to be 
required for erythropoiesis in a PhZ-induced erythropoiesis mouse model. It is 
possible that the acute HIF-2α activation following PhZ treatment is not sufficient 
to increase Fpn1 expression in comparison with the chronic activation seen with 
a low iron diet (27).  In addition, basal Fpn1 expression appears to be sufficient 
to transport iron, despite increased iron uptake due to increased DcytB and Dmt1 
expression. Together, these data suggest that regulation of Fpn1 expression is 
more important in low iron treatment than erythropoiesis, despite the increase in 
iron absorption in both cases. 
 Interestingly, in PhZ-treated mice, liver hepcidin expression was strongly 
repressed despite the mice having high serum iron levels. A similar phenomenon 
is observed in mouse models and patients with β-thalassemia. Hypoxia and EPO 
have been shown to repress hepcidin levels, and the increase in hypoxia and or 
EPO due to ineffective erythropoiesis may override the increase in hepcidin due 
to high serum iron levels (45, 46).  Further experiments are needed to elucidate 
the role of hepcidin in erythropoiesis. Although the role of hepcidin in 
erythropoiesis is unclear, this study has clearly demonstrated an essential role of 
intestinal hypoxia sensing and HIF-2α activity in the regulation of erythropoiesis. 
HIF-2α-dependent increases in DcytB and Dmt1 at the mRNA and protein levels 
are required for the increased systemic iron demand during erythropoiesis. 
These findings present new therapeutic opportunities for treatment of injuries and 
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diseases involving erythropoiesis. Thalassemia major leads to severe iron 
overload and is treated with chelation therapy (9, 10).  It would be beneficial to 
explore targeted abrogation of intestinal HIF-2α activity, which would reduce iron 
absorption and could alleviate iron overload. Conversely, intestinal HIF-2α 
agonists could be used to increase intestinal iron absorption, which could help 
control iron deficiency anemia without requiring oral iron supplementation. HIF-2α 
is a central regulator of intestinal iron absorption, and more studies are needed to 
determine how modulation of intestinal HIF-2α activity can be used to treat 
diseases of iron overload and iron deficiency anemia. 
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Figure 2.1.  PhZ-induced hemolysis activates expression of EPO in the 
kidney and iron absorption genes in the small intestine. Wild-type mice were 
injected twice 24 h apart with 60 mg of PhZ/kg of body weight or with normal 
saline (Control) and killed 2 days later. qPCR was performed in the kidney or 
liver for Epo and hepcidin (Hepc) (A) or in the duodenum for Dmt1, Dcytb, and 
Fpn1 (B). Expression was normalized to β-actin. Values are expressed as -fold 
change compared with untreated controls. Four to five animals for each 
treatment group were assessed. Statistical analyses were performed using 
Student's t test. Each bar represents the mean ± S.D. **, p < 0.01; ***, p < 0.005; 








Figure 2.2.  Erythropoietic induction of iron absorption genes in the small 
intestine is HIF-2α-dependent. Wild-type (Hif-2αF/F) and intestinal HIF-2 knock-
out (Hif-2αΔIE) mice were treated with PhZ or saline (control) and killed 48 h post-
treatment. qPCR was performed in the duodenum for Dmt1, Dcytb, and Fpn1 (A) 
or in the kidney for Epo (B). Expression was normalized to β-actin. Values are 
expressed as -fold change compared with untreated controls. C, Hif-2αF/F and 
Hif-2αΔIE mice were treated with PhZ or saline (control (Con)) and killed 48 and 
72 h post-treatment. Western blot analysis measuring Dmt1a and DcytB 
expression in membrane extracts and Coomassie Blue staining of total 
membrane proteins were assessed for loading controls. D, immunofluorescence 
staining of Fpn1 in the duodenums of Hif-2αF/F and Hif-2αΔIE mice following PhZ 
treatment. Four to five animals for each treatment group were assessed. 
Statistical analyses were performed using Student's t test. Each bar represents 
the mean ± S.D. *, p < 0.05; **, p < 0.01; n.s., not significant. For Western blot 
analysis and immunofluorescence, a representative image from an individual 





Figure 2.3.  PhZ treatment induces HIF-2α (but not HIF-1α) expression in the 
small intestine. A, Western blot analysis of duodenal nuclear extracts for HIF-1α 
and HIF-2α following PhZ or saline (Control) treatment. Hypoxia-treated Caco-2 
cells were used as a positive control (+C) for HIF-1α. Expression was normalized 
to RAN protein expression. B, tissue non-heme iron quantification of the 
duodenums of PhZ- and saline-treated mice. Four to five animals for each 
treatment group were assessed. For Western blot analysis, representative 


















Figure 2.4.  HIF-2α is stabilized by hypoxia in the small intestine following 
PhZ treatment. A, qPCR analysis of duodenal Hif-2α mRNA expression 
following PhZ or saline (Control) treatment in wild-type mice. B, Western blot 
analysis of Caco-2 cells treated with recombinant human EPO under normoxia 
and hypoxia for 24 h. Expression was normalized to GAPDH protein expression. 
C, Western blot analysis of nitroimidazole-protein adducts in extracts from the 
duodenums and lungs of PhZ-treated and control (Con) wild-type mice. 
Expression was normalized to GAPDH. Four to five animals for each treatment 
group were assessed. For Western blot analysis, a representative image from an 











Figure 2.5.  Intestinal HIF-2 expression is critical for the erythropoietic 
increase in serum iron. Wild-type (Hif-2αF/F) and intestinal HIF-2 knock-out (Hif-
2αΔIE) mice were treated with PhZ or saline (Control), and sera were collected 2 
(2d) and 7 (7d) days after the last injection. Serum was assayed for iron content. 
Four to five animals for each treatment group were assessed. Statistical analyses 

















Figure 2.6.  Intestinal HIF-2 expression is essential for erythropoiesis. Wild-
type (Hif-2αF/F) and intestinal HIF-2 knock-out (Hif-2αΔIE) mice were treated with 
PhZ or saline (Control), and blood was collected 2 (2d) and 7 (7d) days after the 
last injection. Complete blood count analysis was performed measuring RBCs 
(A), HCT (B), and Hb (C). Four to five animals for each treatment group were 
assessed. Statistical analyses were performed using Student's t test. Error bars 














Figure 2.7.  HIF-2 is a central regulator of erythropoiesis. Following 
hemolysis, the kidney and intestine experience hypoxia due to poor oxygen 
delivery. In the kidney, HIF-2α is stabilized, allowing it to bind to and activate the 
Epo promoter. In the small intestine, HIF-2α activates the Dcytb and Dmt1 genes, 
increasing iron absorption. Increased levels of circulating EPO and iron stimulate 
erythropoiesis and supply new erythrocytes with iron for hemoglobin production. 
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β-thalassemia is a highly prevalent genetic disorder characterized by 
anemia caused by inefficient erythropoiesis, which leads to pathological iron 
overload. The increase in tissue iron is the major cause of morbidity and mortality 
in patients with β-thalassemia, however the mechanism is unclear.  In this study 
we demonstrate that expression of the intestinal apical iron absorption genes 
ferric reductase (DcytB) and divalent metal transporter-1 (DMT1) were increased 
in β-thalassemic mice, correlating to the robust iron overload that is observed. 
Systemic hypoxia and intestinal hypoxia-inducible factor 2α (HIF-2α) activation 
was evident early in mouse models of β-thalassemia. Intestinal HIF-2α is a 
transcription factor that is essential for increased iron absorption during iron 
deficiency and erythropoiesis. To assess the role of the intestine and HIF-2α in 
thalassemic iron overload, mice with an intestinal HIF-2α disruption were 
assessed in two models of β-thalassemia. The increase in intestinal iron
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  This Chapter represents a submitted manuscript:  Anderson ER, Xue X, Taylor 
M, Ramakrishnan S, Martin A, Gardenghi S, Rivella S, and Shah YM (2012). 




absorptive genes was completely abolished in β-thalassemic mice containing a 
genetic disruption of intestinal HIF-2α.  Moreover, these mice did not display 
tissue iron overload. Further mechanistic studies demonstrate that loss of 
intestinal HIF-2α signaling led to decreased iron absorption and increased iron 
mobilization from the liver without worsening the anemia. These data 
demonstrate that dysregulation of intestinal hypoxia and HIF-2α signaling is 
critical for iron overload during the progression of β-thalassemia and may be a 
novel therapeutic target.   
 
Introduction 
β-Thalassemia is a congenital blood disorder characterized by partial or 
complete loss of the β-globin gene product. Patients that exhibit suboptimal 
expression of the β-globin gene do not require blood transfusion for survival, but 
exhibit increased iron absorption and iron overload. This condition has been 
defined as β-thalassemia intermedia or non-transfusion dependent thalassemia 
(1).  Increased iron loading in the disease, particularly in the liver, is associated 
with increased morbidity (2).  Since the main cause of death in β-thalassemia is 
iron overload, a major focus has been to investigate the mechanisms involved in 
iron accumulation. A mouse model of β-thalassemia intermedia (Hbbth3/+) was 
developed that recapitulates the human phenotype (3). These mice have a 
heterozygous deletion in the β-minor and β-major chain of hemoglobin. Hbbth3/+ 
mice develop severe anemia. Moreover, this model develops progressive iron 
overload in the absence of blood transfusions, demonstrating that increased iron
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absorption plays a critical role in the disease pathogenesis. The mechanism of 
increased iron absorption is unclear and has not been targeted therapeutically in 
humans (4).   
The liver is a central sensor and regulator of iron homeostasis, and 
examination of gene expression in thalassemic livers revealed a strong decrease 
in hepcidin expression (5, 6).  Hepcidin is a small peptide produced in the liver 
and secreted into the bloodstream that controls systemic iron homeostasis (7).  
Hepcidin acts by binding to ferroportin (Fpn1), the only known mammalian iron 
exporter, which leads to its internalization and degradation (8).  Fpn1 is primarily 
expressed on enterocytes and macrophages of the reticuloendothelial system, 
thus hepcidin acts to limit both duodenal iron absorption and release of iron from 
stores (9, 10).  The prevailing thought is that the decrease in liver hepcidin during 
the progression of β-thalassemia is a critical factor in the hyperabsorption of iron. 
Increasing hepcidin levels inhibited iron overload in mouse models of β-
thalassemia (11), however serum and tissue iron are not completely corrected. 
Moreover, the decrease in hepcidin expression is age dependent. A significant 
decrease in hepcidin expression is observed at 2-months of age, but normalized 
similar to wild-type mice at 5-months of age (6). Hepcidin expression does not 
correlate to intestinal Fpn1 expression in mouse models of β-thalassemia. An 
increase in intestinal Fpn1 expression is observed in older (12-months) but not 
young (2-months or 5-months) β-thalassemic mice, whereas tissue iron overload 
is evident in young mice. (6). Lastly, it has been shown that hepcidin exerts a 
limited effect on intestinal Fpn1 expression (12). Together, these data suggest
	  
	  60	  
that other pathways in addition to hepcidin may mediate the increased iron 
absorption in β-thalassemia.   
Intestinal oxygen sensing is essential for adaptive increases in iron 
absorption. Intestinal hypoxia-inducible factor 2 alpha (HIF-2α) is a critical 
regulator of iron absorption in the settings of iron deficiency, erythropoiesis, and 
hepcidin deficiency (13-16).  HIF-2α is a member of the family of hypoxia-
inducible transcription factors which control the cellular and systemic response to 
oxygen deficiency (17). Recently, we have shown that the apical ferric reductase 
and iron importer, DcytB and Dmt1 respectively (18, 19), and the basolateral iron 
exporter Fpn1 (20) are direct HIF-2α target genes (13, 14). Despite the critical 
role of these apical transporters in iron absorption, no studies have examined the 
expression of these genes in β-thalassemia in mechanistic detail. Since the β-
thalassemic mice develop iron overload without blood transfusions, it is an ideal 
model for studying the role of iron absorption in the progression of this disease.  
In this study, an intestinal hypoxia-HIF-2α signaling axis was shown to be critical 
in the iron overload associated with β-thalassemia. Blocking intestinal HIF-2α 
signaling led to decreased iron absorption and increased iron mobilization from 
the liver, providing a novel therapeutic target for patients with β-thalassemia.  
 
Results and Discussion 
β-Thalassemic mice exhibit systemic and duodenal hypoxia 
Consistent with previous reports, 2-month old Hbbth3/+ mice had lower liver 
hepcidin expression compared to littermate controls Hbb+/+ (Fig. 3.1A) (6).  
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However, no change in duodenal Fpn1 protein expression was observed, 
suggesting that mechanisms in addition to hepcidin are critical for the iron 
overload in β-thalassemic patients (Fig. 3.1B). β-thalassemia is characterized by 
severe anemia and iron overload due to ineffective erythropoiesis. A mouse 
model of anemia demonstrated increased iron absorption in an intestinal HIF-2α-
dependent manner (15).  In order to determine if mice with β-thalassemia are 
similarly hypoxic, the hypoxia reporter mouse, ODD-luc (21), was crossed with 
the Hbbth3/+ mice. In vivo luminescence imaging of mice from this cross 
demonstrated that 3-week old thalassemic mice are systemically hypoxic (Fig. 
3.1C).  In order to obtain better resolution, the duodenum was excised and 
imaged ex vivo.  The duodenum was more hypoxic in the β-thalassemic model 
compared to wild-type littermates (Hbb+/+), suggesting that the increased iron 
absorption in β-thalassemia could be due to intestinal hypoxia (Fig. 3.1D).  Since 
intestinal HIF-2α is a critical regulator of iron absorption (13, 14, 22), Western 
blot for duodenal HIF-2α was performed on Hbb+/+ and Hbbth3/+ mice.  HIF-2α 
protein was stabilized in the duodenum of Hbbth3/+ mice, demonstrating that 
increased iron absorption could be mediated by HIF-2α (Fig. 3.1E). 
 
β-Thalassemic mice hyperabsorb iron in a HIF-2α-dependent manner  
Bone marrow transplantation (BMT) of Hbbth3/+ bone marrow into irradiated wild-
type syngeneic mice leads to stable ineffective erythropoiesis and iron overload, 
hallmarks of β-thalassemia. This provides a powerful and rapid means to assess 
genes critical in the disease progression of β-thalassemia (3).  In order to 
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investigate the role of intestinal HIF-2α in thalassemic iron absorption, intestinal 
HIF-2α knockout mice (Hif-2αΔIE) or littermate controls (Hif-2αF/F) were lethally 
irradiated and transplanted with Hbbth3/+ bone marrow.  One-month following 
BMT, expression of duodenal iron transporter genes was analyzed using 
Quantitative Real-Time PCR (qPCR). The mRNA level of Fpn1 was not 
significantly changed, however the expression of the apical iron transporters 
Dmt1 and DcytB were significantly increased in Hif-2αF/F mice that were 
subjected to BMT from Hbbth3/+ donors (Table 3.1).  These data demonstrate that 
the apical iron transporters are increased early in the pathogenesis of iron 
overload in β-thalassemia.  To further understand the mechanistic basis for the 
increase in Dmt1 and DcytB, bone marrow from Hbbth3/+ mice was transplanted 
into Hif-2αΔIE mice. The increase in Dmt1 and DcytB was completely abolished in 
the Hif-2αΔIE mice (Table 3.1).  Consistent with these changes, the increase in 
liver iron was entirely ameliorated in the Hif-2αΔIE mice. Interestingly, inhibition of 
iron absorption in Hif-2αΔIE mice did not adversely impact hematologic 
parameters in comparison to Hbbth3/+ transplanted bone marrow in wild-type 
littermates (Table 3.1).  
 
Increased iron absorption and tissue iron overload in a genetic model of β-
thalassemia is dependent on HIF-2α. 
Radiation that is required for the BMT model of β-thalassemia can cause small 
intestinal atrophy and apoptosis (23). To confirm the role of the intestinal HIF-2α 
response in thalassemic iron overload without the confounding effects of 
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radiation, the Hif-2αΔIE and Hif-2αF/F mice were crossed to the Hbbth3/+ mice. The 
increase in Dmt1 and DcytB mRNA that was observed in the BMT model of β-
thalassemia was recapitulated in the Hbbth3/+/Hif-2αF/F mice and this increase was 
abolished in Hbbth3/+/Hif-2αΔIE mice (Fig. 3.2A-B).  Protein levels of the iron 
transporters Dmt1 and DcytB were decreased in 2-month old Hbbth3/+/Hif-2αΔIE 
mice compared to Hbbth3/+/Hif-2αF/F mice (Fig. 3.2C). When assessed for iron 
content by enhanced Prussian blue staining, Hbbth3/+/Hif-2αF/F mice exhibited 
significantly higher accumulation of liver iron and spleen iron than wild-type 
littermates at 2-months of age (Fig. 3.2D). Disruption of intestinal HIF-2α in the β-
thalassemia model resulted in normalization of liver iron similar to the levels 
observed in wild-type mice (Fig. 3.2D). Furthermore, Hbbth3/+/Hif-2αΔIE mice 
demonstrate a slight, but not statistically significant improvement in 
hematological parameters compared to Hbbth3/+/Hif-2αF/F mice (Fig. 3.2E-G).  
Together, the data demonstrate that HIF-2α is critical in the pathogenesis of iron 
accumulation in β-thalassemia. In addition, disruption of HIF-2α did not worsen 
anemia, suggesting that HIF-2α may be an efficacious therapeutic target in the 
treatment of β-thalassemia. 
 
Loss of intestinal HIF-2α promotes tissue iron mobilization 
Our data demonstrate that activation of HIF-2α signaling is critical for tissue iron 
accumulation in mouse models of β-thalassemia. Blocking intestinal HIF-2α 
restricts iron absorption leading to a decrease in tissue iron accumulation. 
However, it is not clear if existing iron that is accumulated in the liver can be 
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cleared or mobilized more efficiently through inhibition of intestinal HIF-2α and 
blocking iron absorption.  To answer this question two models were used that 
increased liver iron independent of intestinal absorption. Phenylhydrazine (PhZ)–
induced hemolysis leads to an increase in liver iron that is poorly mobilized over 
time (24).  Hif-2αF/F mice were treated with PhZ and liver iron was measured at 
two- and seven-days after treatment.  Hif-2αF/F mice had a significant increase in 
liver iron two-days after PhZ treatment, and levels remained high one-week 
following treatment (Fig. 3.3A).  Similar to wild-type mice, PhZ treatment of Hif-
2αΔIE mice causes substantial liver iron loading two-days following treatment (Fig. 
3.3A).  However, seven days after PhZ treatment liver iron content dropped to 
normal levels in the Hif-2αΔIE mice  (Fig. 3.3A).  In the second model, iron stores 
were boosted by a 100 µg injection of iron dextran four-days prior to bleeding for 
three consecutive days.  Mice were then analyzed five-days after the last 
phlebotomy.  Hif-2αF/F mice effectively mobilized spleen iron, but were unable to 
mobilize liver iron (Fig. 3.3B).  Hif-2αΔIE mice were able to effectively mobilize iron 
from the liver and spleen (Fig. 3.3B) Together these data demonstrate that 
inhibition of iron absorption by intestinal HIF-2α disruption allows rapid 
mobilization of iron to meet the demand of erythropoiesis.  The data presented 
here demonstrate that inhibition of intestinal HIF-2α, in conjunction with existing 
therapies, would drastically accelerate mobilization of iron stores in the treatment 





Animals and Treatments 
 Hif-2αΔIE, Hbbth3/+, and ODD-luc animals were described previously (3, 14, 
21).  All mice were analyzed at 2-months of age.  PhZ (Sigma, St. Louis MO) 
treatment was performed as previously described (15).  For BMT, mice received 
12 Gy of total body irradiation split into two doses of 6 Gy in an interval of 4- 
hours, and BMT was performed the day after irradiation.  In vivo and ex vivo 
luminescence imaging was performed as previously described in 3-week old 
mice (21).  Iron-dextran (Sigma) was diluted in sterile normal saline and 
administered by intrascapular injection.  For phlebotomy experiments, 200-300 
µL of blood was removed by submandibular bleeding for 3 consecutive days. 
Complete blood count (CBC) analysis was performed by the Unit for Laboratory 
Animal Medicine Pathology Core for Animal Research.  Tissues were flash 
frozen in liquid nitrogen and stored at -80o C until analysis.  All animal studies 
were carried out in accordance with Institute of Laboratory Animal Resources 
guidelines and approved by the University Committee on the Use and Care of 
Animals at the University of Michigan. 
 
Western Blot 
 Tissues were homogenized and lysed in radioimmunoprecipitation assay 
buffer (RIPA) for detection of HIF-2α and GAPDH.  Membrane protein isolation 
was performed for the detection of Dmt1, DcytB, and Fpn1 as described 
previously (14). Antibodies against HIF-2α (Novus Biologicals, Littleton CO), 
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GAPDH (Santa Cruz Biotech, Santa Cruz CA), Dmt1, DcytB, and Fpn1 (Alpha 
Diagnostic International Inc., San Antonio TX) were used. 
 
Iron Staining 
 Tissues were fixed in 10% Formalin in PBS overnight.  Tissues were 
processed, embedded in paraffin, and sectioned at 7 µm thickness.  Sections 
were deparaffinized and hydrated before incubation in a solution of 1% HCl and 
1% potassium ferrocyanide for 30 minutes and then washed in deionized water 
before treatment with 0.025% 3,3-diaminobenzidine and .005% H2O2 for 30 
minutes.  Slides were counterstained with Nuclear Fast Red.  Reagents were 
purchased from Sigma. 
 
Real-time quantitative PCR (qPCR) 
 RNA isolation, reverse transcription, qPCR, and primers used for qPCR 
were described previously (15). 
 
Non-heme iron quantitation 
 Tissues were weighed and homogenized in ddH2O to a concentration of 
100 mg/mL.  The homogenate was mixed 1:1 with a solution of 1M HCl and 10% 
trichloroacetic acid (TCA) before incubation at 95o C for 1 hour.  Debris was 
pelleted and iron in the supernatant was quantified using ferrozine in comparison 





Results are expressed as mean ± S.D. P values were calculated by 
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Figure 3.1. β-thalassemia leads to an increase in systemic and duodenal 
hypoxia.  Control and thalassemic mice were analyzed 1-month after bone 
marrow transplant. A) mRNA was extracted from liver and hepcidin was 
quantified by qPCR. Expression was normalized to β-actin. B) Membrane protein 
was extracted from duodenums and Western Blot was performed for Fpn1. 
Loading was confirmed by coomassie stain. C) ODD-luc mice were crossed with 
Hbbth3/+ mice and examined at 3-weeks of age. In vivo analysis of hypoxia in 
Hbbth3/+ mice compared with littermate controls. D) Ex vivo imaging of the 
isolated duodenum from Hbbth3/+ mouse and a littermate control. E) Western blot 
for duodenal HIF-2α in wild-type and Hbbth3/+ mice at two-months of age. GAPDH 
was used as a loading control. Each bar represents the mean value ± S.D. 












Figure 3.2. Intestinal HIF-2α is essential for tissue iron overload in β-
thalassemia.  Hif-2αF/F and Hif-2αΔIE mice crossed with the Hbbth3/+ mice and 
analyzed at 2-months of age.  qPCR analysis for duodenal A) DcytB and B) 
Dmt1. Expression was normalized to β-actin. C) Western blot analysis for Dmt1 
and DcytB in Hbbth3/+/Hif-2αF/F and Hbbth3/+/Hif-2αΔIE mice. Loading was 
determined by Coomassie stain. D) Hbbth3/+/Hif-2αF/F and Hbbth3/+/ 
Hif-2αΔIE mice were analyzed for spleen and liver iron content by DAB-enhanced 
prussian blue staining. Liver non-heme iron quantitation is in parenthesis below 
stained sections. E) Red blood cell (RBCs) count, F) hemoglobin (Hb), G) and 
hematocrit were analyzed from Hbbth3/+/Hif-2αF/F and Hbbth3/+/Hif-2αΔIE mice. 
Each bar represents the mean value ± S.D. not significant (n.s), *p<0.05 




Figure 3.3. Intestinal disruption of HIF-2α leads to rapid mobilization of liver 
iron. A) Hif-2αF/F and Hif-2αΔIE mice were treated with phenylhydrazine (PhZ) and 
liver non-heme iron was quantitated 2 and 7 days following the last PhZ injection. 
B) Hif-2αF/F and Hif-2αΔIE mice were loaded with 100 µg iron dextran, bled 3 
consecutive days, and allowed to recover for 5 days. Liver and spleen non-heme 
iron content was quantitated from from phlebotomized Hif-2αF/F and Hif-2αΔIE 
mice. Each bar represents the mean value ± S.D. *p<0.05 compared to untreated 
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The Hypoxia-Inducible Factor-C/EBPα Axis Controls Ethanol-Mediated 
Hepcidin Repression* 
Abstract 
 Hepcidin is a liver-derived peptide hormone and the master regulator of 
systemic iron homeostasis. Decreased hepcidin expression is a common feature 
in alcoholic liver disease (ALD) and in mouse models of ethanol loading. 
Dysregulation of hepcidin signaling in ALD leads to liver iron deposition, which is 
a major contributing factor to liver injury. The mechanism by which hepcidin is 
regulated following ethanol treatment is unclear. An increase in liver hypoxia was 
observed in an acute ethanol-induced liver injury model. The hypoxic response is 
controlled by a family of hypoxia-inducible transcription factors (HIFs), which are 
composed of an oxygen-regulated alpha subunit (HIFα) and a constitutively 
present beta subunit, aryl hydrocarbon receptor nuclear translocator (HIFβ/Arnt). 
Disruption of liver HIF function reversed the repression of hepcidin following 
ethanol loading. Mouse models of liver HIF overexpression demonstrated that 
both HIF-1α and HIF-2α contribute to hepcidin repression in vivo. Ethanol 
treatment led to a decrease in CCAAT-enhancer-binding protein alpha (C/EBPα)
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
*	  This chapter represents a published manuscript:  Anderson ER, Taylor M, Xue 
X, Martin A, Moons DS, Omary MB, Shah YM (2012).  “The hypoxia-inducible 
factor-C/EBPα axis controls ethanol-mediated hepcidin repression.”  Molecular 
and Cellular Biology 
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protein expression in a HIF-dependent manner. Importantly, adenoviral rescue of 
C/EBPα in vivo ablated the hepcidin repression in response to ethanol treatment 
or HIF overexpression. These data provide novel insight into the regulation of 
hepcidin by hypoxia and indicate that targeting HIFs in the liver could be 
therapeutic in ALD. 
 
Introduction 
 Patients with alcoholic liver disease (ALD) accumulate iron in the liver (1).  
Free iron enhances reactive oxygen species (ROS) production in the liver, 
leading to oxidative stress, which is a major contributing factor to alcohol-induced 
liver injury (2).  The development of liver fibrosis positively correlates with liver 
iron staining in ALD, and the presence of iron deposits in the liver of patients with 
alcoholic cirrhosis is predictive of death (3).  There is compelling evidence that 
iron-mediated oxidative stress may be an important pathological mechanism for 
the increased incidence of hepatocellular carcinoma in individuals with hepatic 
iron overload who consume alcohol (4).  Lastly, hepatic iron overload increases 
the risk of insulin resistance and diabetes due to hepatic inflammation (5). 
 Hepcidin is a small antimicrobial peptide produced in the liver and 
secreted into the bloodstream which regulates systemic iron homeostasis (6, 7).  
Hepcidin functions by binding to the only known mammalian iron exporter, 
ferroportin (FPN), which leads to its internalization and degradation (8).  FPN is 
primarily expressed on macrophages of the reticuloendothelial system and 
absorptive enterocytes in the small intestine (9).  Thus, hepcidin acts to restrict
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intestinal iron absorption and prevent release of iron from stores. Conversely, 
hepcidin deficiency leads to increased iron absorption and mobilization of iron 
stores, which can cause iron overload (9, 10).  Previous publications have shown 
that in rodents and humans, hepcidin is downregulated in response to ethanol 
treatment (11-18).  Moreover, it has been shown that the increase in liver iron 
following alcohol consumption in ALD patients is directly due to low hepcidin 
expression (11-18).  However, the mechanism(s) by which hepcidin is 
dysregulated following ethanol exposure remains unclear. 
 The present study demonstrated that alcohol treatment in mice led to a 
robust hypoxic response compared to that seen with vehicle-treated mice and 
that this hypoxia was associated with a strong inhibition of hepcidin expression. 
Changes in gene expression during hypoxia are primarily controlled by a family 
of hypoxia-inducible transcription factors (HIFs) (19).  HIFs consist of an oxygen-
regulated alpha subunit (HIFα) and a constitutively expressed beta subunit, aryl 
hydrocarbon receptor nuclear translocator (HIFβ/Arnt). Under conditions of 
normal oxygen tension, the HIFα subunit is hydroxylated by prolyl hydroxylase 
enzymes (PHDs) at specific proline residues. This modification is recognized by 
the protein coded by the Von Hippel-Lindau tumor suppressor gene (Vhl), which 
is part of an E3 ubiquitin ligase complex. VHL facilitates ubiquitination of the HIFα 
subunit, which leads to its subsequent degradation by the proteasome. Genetic 
disruption of Vhl results in the presence of constitutively active HIF in vivo and is 
a well-characterized model to study HIF function (20, 21).  Under conditions of 
low oxygen, PHD activity is decreased and the HIFα subunit is stabilized, which 
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allows it to accumulate in the cytoplasm and then translocate into the nucleus 
and heterodimerize with Arnt. The HIF complex binds to promoters of many 
genes involved in the hypoxic response and activates their transcription (22). 
 Hypoxia is known to repress hepcidin, and several mechanisms for the 
hypoxic repression have been proposed (23-26).  However, the precise 
mechanism is still unclear. Moreover, the role of hypoxia in the repression of 
hepcidin in ALD has not been examined. The present report clearly demonstrates 
that alcohol-induced hepcidin repression can be blocked by a conditional 
disruption of Arnt in the hepatocytes, which leads to total loss of HIF 
transcriptional activity. Furthermore, we identified a novel signaling cascade that 
involved HIF-mediated degradation of CCAAT-enhancer-binding protein alpha 
(C/EBPα). C/EBPα overexpression rescued the repression of hepcidin observed 
with ethanol loading and partially reversed the repression caused by HIF 
overexpression. These data demonstrate a novel connection between hypoxia 
and hepcidin expression in vivo and could lead to development of therapies 
targeting HIFs or C/EBPα in the liver of ALD patients. 
 
Materials and Methods 
Animal experiments 
 VhlF/F, VhlF/F Hif-1αF/F, VhlF/F Hif-2αF/F, and VhlF/F ArntF/F mice were 
previously described (27) and are in the same genetic background 
(129S6/SvEv). Temporal liver-specific knockouts constructed using serum 
albumin enhancer-driven tamoxifen-inducible estrogen receptor-conjugated Cre 
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(SA-Cre-ERT2) were achieved as previously described (28).  In these animals, 
tamoxifen treatment causes the estrogen receptor Cre fusion protein to 
translocate to the nucleus, which leads to Cre-mediated excision of floxed genes. 
The hypoxia reporter mouse (oxygen-dependent-degradation domain–luc [ODD-
luc]) animal model was obtained from Jackson Laboratories (Bar Harbor, ME) 
and has been described previously (29).  For viral expression, animals were 
administered 1 × 109 PFU of purified virus in 200 µl of normal saline solution by 
tail vein injection. Blood was collected by submandibular bleeding. For ex vivo 
imaging experiments, animals were administered d-luciferin (Promega Corp., 
Madison, WI) (50 mg/kg of body weight) by intraperitoneal injection, and tissues 
were imaged after 15 min using an IVIS 200 imaging system (Caliper Life 
Sciences, Hopkinton, MA). For tamoxifen experiments, tamoxifen (Sigma-Aldrich, 
St. Louis, MO) (2 mg in corn oil) was injected intraperitoneally once daily for two 
consecutive days and mice were sacrificed 5 days or 2 weeks later. For ethanol 
experiments, mice were gavaged every 12 h with increasing doses of 25% 
ethanol starting at 5 mg/kg and increasing by 0.5-mg/kg increments each 
treatment. Animals were euthanized 12 h after the last gavage of 7.5 mg/kg. The 
mice were housed in a light- and temperature-controlled room and were given 
water and chow ad libitum. Tissues were harvested and used fresh or were flash-
frozen in liquid nitrogen and stored at −80°C for future use. All animal studies 
were carried out in accordance with Institute of Laboratory Animal Resources 
guidelines and approved by the University Committee on the Use and Care of 




 Huh7 and HEK293A cells were maintained at 37°C in 5% CO2 and 21% 
O2. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and antibiotics-antimycotics. 
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer, and Western 
blot analysis was performed. For transfection experiments, HEK293A cells were 
transfected using FuGENE 6 transfection reagent (Promega Corporation, 
Madison, WI) 24 h before hypoxia treatment. For adenoviral infection 
experiments, cells were treated at a multiplicity of infection (MOI) of virus of 100 
24 h before sample collection. Viruses were purified by the University of Michigan 
Vector Core. MG132 (Cayman Chemical, Ann Arbor, MI) was used at a 
concentration of 10 µM for 24 h. For hypoxia experiments, cells were incubated 
in 1% O2 and 5% CO2 with balance N2 at 37°C for 24 h. 
Western blotting 
 Tissues were homogenized and lysed in RIPA buffer for whole-cell 
extracts, and nuclear proteins were isolated using an NE-PER nuclear extraction 
kit (Pierce, Rockford, IL). Proteins were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose 
membranes using standard methods. Membranes were incubated with 
antibodies against C/EBPα (sc-61), histone H1 (sc-8030), HIF-1α (sc-10790), 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (sc-25778; Santa 
Cruz Biotech, Santa Cruz, CA). Histone H3 (catalog no. 4499) and pSmad1, -5, 
and -8 (pSmad1/5/8; catalog no. 9511) antibodies were from Cell Signaling 
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Technology (Danvers, MA). HIF-2α (NB100-122) antibody was from Novus 
(Novus Biologicals, Littleton, CO). All antibodies were used at a 1:1,000 dilution. 
Real-time quantitative PCR 
 RNA from fresh or frozen tissue and cells was isolated using Isol-RNA 
lysis reagent (Prime, Gaithersburg, MD) and subjected to reverse transcription 
using Moloney murine leukemia virus (MMLV) reverse transcriptase (RT; Fisher 
Scientific, Waltham, MA). cDNA was quantified using SYBR green dye and run 
on a 7900HT Fast real-time RT-PCR system (primers are listed in Table 4S1 in 
the supplemental material). Threshold cycle (CT) values were normalized to β-
actin and expressed as fold differences from control values. 
Site-directed mutagenesis 
 Site-directed mutagenesis was performed using a QuikChange II XL site-
directed mutagenesis kit (Agilent Technologies, Santa Clara, CA) (primers are 
listed in Table 4S1 in the supplemental material). 
Measurement of serum EPO 
 Serum erythropoietin (EPO) was measured using a mouse enzyme-linked 
immunosorbent assay (ELISA) kit per the manufacturer's recommendation 
(Abcam, Cambridge, MA). 
 
Results 




 Mice were treated with increasing concentrations of ethanol by oral 
gavage every 12 h for a total of 5 doses. This model parallels the binge drinking 
observed in a significant proportion of ALD patients. Livers collected from control 
and ethanol-loaded mice were examined for gene expression. Hepcidin 
expression was strongly repressed in response to ethanol treatment (Fig. 4.1A), 
whereas EPO expression in the kidney was not statistically significant (P = 0.23) 
(Fig. 4.1A).  In order to determine the mechanism by which hepcidin is 
repressed, a number of known hepcidin regulatory genes were examined by real-
time quantitative PCR (qPCR). No changes in bone morphogenetic protein (Bmp) 
ligands or their respective receptors were observed following ethanol treatment 
(Fig. 4.1B).  There was an increase in transferrin receptor 1 (Tfr1) expression 
(Fig. 4.1C).  Moreover, ethanol treatment significantly decreased expression of 
Tmprss6, which is a critical regulator of hepcidin expression (Fig. 4.1C) (30).  
However, these changes could not account for the repression of hepcidin 
expression seen following ethanol treatment, as Tmprss6 is a negative regulator 
of hepcidin expression and an increase in Tfr1 expression should increase liver 
iron uptake and thus increase hepcidin expression. There was a significant 
repression of mothers against decapentaplegic homolog 9 (Smad8) (Fig. 4.1D).  
The Smad family of transcription factors is well characterized in their regulation of 
hepcidin expression (31).  However, when phosphorylated proteins Smad1, -5, 
and -8 were examined by Western blot analysis, no significant changes were 
found (Fig. 4.1E), demonstrating that an alternate mechanism is responsible for 
the repression of hepcidin. 
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Hypoxic signaling is critical in ethanol-mediated hepcidin repression 
 In order to test the possibility that hypoxia is involved in the repression of 
hepcidin during ethanol loading, the hypoxia reporter mouse (ODD-luc) was 
utilized. This mouse model expresses a fusion protein consisting of the oxygen-
dependent-degradation domain (ODD) from HIF-1α fused to luciferase. This 
protein is constitutively expressed in all tissues but is stable only under 
conditions where endogenous HIF would also be stabilized. Thus, this model 
allows detection of hypoxia in live mice or specific detection of hypoxia in a tissue 
ex vivo (29).  ODD-luc mice treated with ethanol showed a strong induction of 
hypoxia in the liver, as seen by ex vivo imaging (Fig. 4.2A).  In addition, Western 
blot analysis was performed on liver nuclear extracts from control and ethanol-
treated mice. HIF-2α expression was strongly increased in response to ethanol 
treatment (Fig. 4.2B).  HIF-1α was not detected, although it is possible that HIF-
1α is stabilized acutely following ethanol treatment and is degraded more rapidly 
than HIF-2α. To assess if liver hypoxia is critical for hepcidin repression following 
ethanol treatment, intravenous administration of adenoviral Cre, which traffics 
specifically to the liver (32), was used to induce recombination in mice containing 
loxP recombination sites flanking exon 6 of Arnt, referred to as ArntF/F mice (33).  
Arnt is the obligate heterodimer partner for HIF1α, HIF2α, and HIF3α; thus, 
disruption results in complete inactivation of HIF signaling. This model of Arnt 
knockdown is preferable to an albumin-Cre-mediated recombination, as it 
eliminates the possibility of developmental effects on hepcidin expression (34).  
Arnt knockdown was validated by qPCR (Fig. 4.2C).  Control mice with intact 
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Arnt expression in the liver had decreased hepcidin expression following ethanol 
treatment. Disruption of Arnt in the liver completely blocked repression of 
hepcidin in response to ethanol loading (Fig. 4.2C).  These data suggest that HIF 
signaling is essential in hepcidin repression by ethanol treatment. 
Repression of hepcidin expression by HIFs does not require erythropoiesis 
 Hypoxia is a well-known but poorly understood repressor of hepcidin 
expression. An initial connection between hypoxia and hepcidin expression was 
made in which direct HIF binding to the hepcidin promoter led to repression (25).  
However, this finding was not uniformly observed (26), thereby leaving the 
relationship between HIF and hepcidin unclear. A recent study demonstrated that 
overexpression of HIFs in the liver caused a decrease in hepcidin expression that 
required erythropoiesis (35).  However, reports of studies that examined 
erythropoietic hepcidin repression make no mention of the repression of hepcidin 
in alcohol loading (36-38).  In addition, a study of VhlR200W homozygote humans, 
who have activated HIF signaling, demonstrated reduced hepcidin levels that did 
not correlate with an increase in serum EPO, suggesting that HIFs could repress 
hepcidin independently of erythropoiesis (39). 
 To understand the role of HIFs in hepcidin repression and to avoid the 
confounding developmental defects of Vhl deletion, a model of inducible liver 
gene knockout was used (28).  Tissues that lack Vhl are unable to degrade the 
HIFα subunit under normal oxygen conditions, leading to constitutive HIF stability 
and activity. VhlF/F mice were crossed with SA-Cre-ERT2 transgenic mice to 
generate a temporal and conditional disruption of Vhl (VhlLivKO) using the 
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tamoxifen-inducible cre fusion protein (40).  In these mice, Cre-mediated 
recombination specifically in the liver is induced by tamoxifen treatment, allowing 
temporal control over gene expression. Moreover, to assess the influence of HIF-
dependent pathways on iron-regulatory gene expression in the liver, mice with a 
double disruption of Vhl and Hif-1α or Hif-2α (Vhl/Hif-1αLivKO and Vhl/Hif-2αLivKO) 
were also assessed. These compound knockouts remove the possibility that the 
effects of Vhl ablation on hepcidin expression are the result of a HIF-independent 
mechanism. By the use of compound conditional liver knockouts, mice with loss 
of Vhl alone or in conjunction with HIF-1α demonstrated a robust decrease in 
hepcidin levels, high EPO expression, and a large increase in circulating EPO 2 
weeks after induction of Cre by tamoxifen treatment (Table 4.1).  Double 
disruption of Arnt and Vhl (Vhl/ArntLivKO) completely inhibits all HIFα function, 
since it is an obligate heterodimer partner for both HIF-1α and HIF-2α. The livers 
of the Vhl/ArntLivKO mice showed a loss of hepcidin repression, demonstrating a 
HIF-dependent mechanism. Surprisingly, compound deletion of Vhl and HIF-2α 
still led to strong hepcidin repression despite the absence of any increase in 
circulating EPO levels (Table 4.1).  These data suggest that there is a HIF-
dependent mechanism of hepcidin repression that does not require enhanced 
erythropoiesis. 
 Examination of gene expression in the liver Vhl knockout mice after 5 days 
demonstrated no change in Bmp ligand or receptor expression (Fig. 4.3A).  
Consistent with ethanol treatment, Tfr1 expression was increased and Smad8 
mRNA expression was significantly decreased following liver Vhl knockout (Fig. 
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4.3 B and C).  However, there was no detectable decrease in the levels of 
phosphorylated Smad proteins (Fig. 4.3D).  These data establish that there is a 
HIF-dependent but Bmp/Smad- and erythropoietin-independent pathway for 
hepcidin repression. 
A decrease in liver C/EBPα protein expression is responsible for hepcidin 
repression by HIFs 
 C/EBPα is a transcription factor that is also critical in maintaining basal 
hepcidin expression (41).  In order to determine whether C/EBPα is involved in 
the repression of hepcidin expression by HIFs, conditional deletion of Vhl was 
performed for different amounts of time. Five days following induction of Cre 
recombination by tamoxifen treatment, hepcidin expression was strongly 
repressed without a decrease in C/EBPα mRNA levels (Fig. 4.4A).  Two weeks 
after recombination, hepcidin mRNA and C/EBPα mRNA levels were both 
decreased (Fig. 4.4A).  Examination of C/EBPα protein expression by Western 
blot analysis showed that liver Vhl knockout alone or in conjunction with HIF-1α 
led to a significant decrease in the protein expression (Fig. 4.4B).  EPO has been 
shown to decrease C/EBPα expression (42).  To completely rule out the role of 
EPO, C/EBPα protein was examined in the mice with the compound Vhl and HIF-
2α knockout. These mice had no increase in EPO or erythropoiesis. The Vhl and 
HIF-2α double-knockout mice demonstrated lower C/EBPα protein expression 
(Fig. 4.4B), whereas the Vhl and Arnt double-knockout mice showed no change 
in C/EBPα protein expression (Fig. 4.4B).  C/EBPα protein expression was 
decreased as early as 1 day after induction of Cre by tamoxifen, demonstrating 
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that the decrease in C/EBPα expression is an early event (Fig. 4.4C).  To test 
whether C/EBPα could rescue hepcidin expression in liver Vhl knockout mice, 
animals were infected with an adenoviral construct expressing C/EBPα. 
Successful adenoviral overexpression was confirmed by Western blot analysis 
(Fig. 4.4D).  Infection of Vhl knockout animals with C/EBPα led to a substantial 
derepression of hepcidin expression (Fig. 4.4E).  To confirm that the green 
fluorescent protein (GFP)-expressing adenovirus infection did not affect hepcidin 
levels, mice infected with adenovirus expressing GFP demonstrated levels of 
expression of hepcidin similar to those seen with uninfected mice (Fig. 4S1).  
These data demonstrate that the repression of hepcidin expression by HIFs is 
mediated by a decrease in C/EBPα protein expression. 
Hypoxia promotes proteasomal degradation of C/EBPα 
 Since the decrease in C/EBPα protein expression was observed 
independently of a change in mRNA, the possibility that hypoxia affects C/EBPα 
protein stability was tested. Huh7 cells, representing a human hepatoma cell line, 
have been used in multiple studies to examine regulatory mechanisms of 
hepcidin expression (9, 43-45).  Treatment of Huh7 cells with hypoxia caused no 
change in endogenous hepcidin expression (Fig. 4.5A).  However, adenoviral 
overexpression of C/EBPα increased hepcidin expression, and this increase was 
abolished by hypoxia treatment (Fig. 4.5A).  In addition, hypoxia treatment did 
not decrease endogenous or exogenous C/EBPα mRNA expression (Fig. 4.5B).  
Western blot analysis of Huh7 protein extracts showed that hypoxia led to a 
decrease in exogenous levels of C/EBPα (Fig. 4.5C).  There was no substantial 
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decrease in the presence of endogenous C/EBPα, which is expressed at very 
low levels in this cell line. This could explain why hypoxia did not decrease 
endogenous hepcidin expression. Studies have shown that C/EBPα is degraded 
through the ubiquitin-proteasome pathway (46).  To determine if this process is 
responsible for hypoxia-dependent C/EBPα destabilization, cultured Huh7 cells 
were treated with the proteasome inhibitor MG132 under hypoxia conditions. 
Proteasome inhibition drastically increased C/EBPα protein stability under 
hypoxia conditions (Fig. 4.5D).  A previous publication showed that 
phosphorylation at serine 193 was critical for proteasomal degradation of 
C/EBPα (46).  To determine if phosphorylation at this site was important for HIF-
mediated C/EBPα degradation, we transfected HEK293A cells with either a wild-
type or an S193A-mutated C/EBPα expression construct and subjected the cells 
to normoxia and hypoxia. HEK293A cells were used, since these cells are easily 
transfected with plasmid DNA. Similar to Huh7 cells, wild-type C/EBPα is 
degraded under hypoxia conditions in HEK293A cells (Fig. 4.5E).  However, the 
S193A mutation abolished the protein degradation, indicating that 
phosphorylation at this site is essential for HIF-mediated C/EBPα degradation. 
Cyclin-dependent kinase 4 has been shown to phosphorylate C/EBPα at S193 
and is regulated by cyclin D. To determine whether HIFs could cause an increase 
in CDK activity, Western blot analysis was performed on liver whole-cell extracts 
from liver Vhl knockout mice. These animals have an increase in liver cyclin D1 
protein (Fig. 4.5F).  Moreover, an increase in cyclin D1 protein was also detected 
in the livers of ethanol-treated mice (Fig. 4.5G).  In conjunction with the in vivo 
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data, these experiments demonstrate that HIF-dependent hepcidin repression is 
mediated by destabilization of C/EBPα protein. 
A HIF-dependent decrease in C/EBPα protein stability is responsible for hepcidin 
repression in ethanol loading 
 To determine whether the HIF-mediated C/EBPα protein decrease was 
relevant to hepcidin repression following ethanol treatment, Western blot analysis 
for C/EBPα was performed on livers from control and ethanol-treated mice. 
Ethanol treatment caused a decrease in C/EBPα protein expression in the liver 
(Fig. 4.6A).  However, mice deficient for Arnt expression in the liver showed no 
decrease in C/EBPα protein expression following ethanol treatment (Fig. 4.6A).  
To test if C/EBPα overexpression could rescue the ethanol-induced repression of 
hepcidin, mice were infected with an adenoviral vector expressing C/EBPα and 
then treated with ethanol. C/EBPα overexpression prevented the decrease in 
hepcidin expression following ethanol treatment (Fig. 4.6B). 
 
Discussion 
 Iron overload in ALD contributes to oxidative stress and tissue damage 
(1).  Investigating the mechanisms behind ethanol-mediated hepcidin repression 
could lead to new therapies to combat iron overload in ALD. This report provides 
novel insight not only into the mechanisms of hepcidin repression following 
ethanol loading but also into the role of HIFs in controlling hypoxic hepcidin 
repression. Mechanisms of hepcidin repression that involve hypoxia, such as 
high-altitude exposure, hemolytic anemia, and phlebotomy, are all complicated 
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by increased erythropoiesis (36, 47, 48).  This study took advantage of a 
temporal liver-specific double disruption of Vhl and HIF-2α, which strongly 
represses hepcidin expression without an increase in the presence of circulating 
erythropoietin. This model allowed delineation of hypoxic and erythropoietic 
pathways for hepcidin expression. Also, the ethanol-loading model described in 
this report represents the first demonstration of the physiological consequence of 
liver hypoxia in the absence of increased erythropoiesis. 
 The present report demonstrates that ethanol-mediated repression of 
hepcidin is accomplished through a HIF-dependent decrease in C/EBPα protein 
stabilization. The proposed mechanism is that ethanol treatment stabilizes HIF in 
hepatocytes, leading to C/EBPα degradation by the proteasome and thus 
preventing it from activating hepcidin (Fig. 4.6C).  The HIF-dependent changes 
that lead to this destabilization remain unclear. Previous studies have shown that 
C/EBPα can be phosphorylated by cyclin-dependent kinases (Cdk) at serine 193, 
subsequently leading to its ubiquitination and degradation through the ubiquitin-
proteasome pathway (46).  Mutation of serine 193 to alanine blocks hypoxia-
induced degradation, suggesting that the HIF and Cdk pathways may interact to 
control C/EBPα stability. Notably, cyclin D1, an important cofactor for Cdk 
activity, is upregulated in a HIF-dependent manner (49, 50). 
 Prior studies have shown that ethanol treatment can lead to a decrease in 
C/EBPα mRNA and DNA-binding activity (11, 15, 51).  Moreover, EPO has been 
shown to decrease levels of C/EBPα mRNA. In the present study, 5 days after 
induction of HIF overexpression, in experiments utilizing the conditionally and 
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temporally disrupted Vhl mice, hepcidin expression was potently repressed and 
C/EBPα mRNA expression was unchanged (Fig. 4.4A).  Two weeks after HIF 
overexpression, both C/EBPα expression and hepcidin mRNA expression were 
strongly repressed (Fig. 4.4A).  At that later time point, the decrease in C/EBPα 
mRNA expression was likely mediated by EPO signaling through its receptor, as 
a previous publication demonstrated that an EPO receptor antibody blocked 
erythropoietic C/EBPα mRNA repression (42).  The rapid destabilization of 
C/EBPα protein by HIFs represents a novel mechanism for HIF-C/EBPα 
interactions. The data presented herein demonstrate that HIF-mediated C/EBPα 
destabilization plays an important role in the liver hypoxic response in vivo. This 
raises the question of whether the mechanism for C/EBPα degradation during 
hypoxia is intact in other tissues as well. For example, mutations in C/EBPα have 
been identified in multiple cases of acute myeloid leukemia (AML) (52) and 
C/EBPα is dysregulated in more than half of patients with the disease (53).  In 
addition, it has been shown that HIF inhibition can selectively kill human AML 
cancer stem cells (54).  Further exploration of this pathway in additional cell 
types could lead to a better understanding of the pathogenesis of C/EBPα-related 
diseases, which could improve therapy. 
 HIF repression of hepcidin is a well-documented observation, and several 
putative mechanisms have been proposed (23-26).  Through an in vivo 
mechanistic assessment, the data in the present paper identify a novel 
erythropoietin-independent mechanism by which HIF represses hepcidin 
expression. It is possible that low levels of hepcidin allow increased activity of 
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iron-dependent enzymes and processes, which could be beneficial, but the 
physiological role of this repression is completely unclear. No publications to date 
have shown the importance of HIF repression of hepcidin in maintaining systemic 
iron homeostasis. Although its normal physiological role is not apparent, the 
present report definitively demonstrates that alcohol induces pathological hypoxia 
and that HIF activity is essential in alcohol-mediated hepcidin repression. This 
finding may be critical in identifying therapies to limit iron-induced injury in ALD 
patients. 
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Fig. 4.1.  Repression of hepcidin during ethanol treatment is independent of 
Bmp/Smad and EPO signaling. Following ethanol treatment, gene expression 
was determined by qPCR analysis of (A) kidney (Kid) EPO and liver (Liv) EPO 
and hepcidin (Hepc) expression, (B) liver expression of Bmp ligands and 
receptors, (C) hepcidin regulatory genes, and (D) Smads. mRNA expression was 
normalized to β-actin. (E) Western blot analysis of pSmad1/5/8 protein from 
whole-cell extracts of liver following ethanol treatment. Loading was normalized 
to GAPDH. n.d., not detected. n = 6 to 8 animals per group. Each bar represents 
the mean ± standard error (SE). *, P < 0.05 as determined by Student's t test; **, 









Fig. 4.2.  HIF signaling in the liver is required for repression of hepcidin 
expression by ethanol treatment. ODD-luc mice were treated with ethanol and 
imaged using an IVIS 200 imaging system. (A) Representative livers from two 
control and two ethanol-treated ODD-luc mice. (B and C) Western blot analysis 
of HIF-1α, HIF-2α, and histone 3 in liver nuclear extracts from control (Con) and 
ethanol-treated (EtOH) mice. Liver-specific Arnt disruption was induced by tail 
vein injection of adenovirus expressing Cre recombinase (Ad-Cre) 3 days before 
ethanol treatment, and (B) hepcidin and (C) Arnt gene expression was analyzed 
in control mice (ArntF/F) and Arnt knockout mice (ArntF/F+Ad-Cre). Gene expression 
was normalized to β-actin. n = 6 to 8 animals per group. Each bar represents the 
mean ± SE. Asterisks denote statistical significance versus control results at P < 



























Fig. 4.3.  Hepcidin repression by HIFs is independent of Bmp/Smad 
signaling. (A, B, and C) VhlF/F and VhlF/F;AlbERcre mice were administered 
tamoxifen (TM), and then mRNAs from livers of the mice were examined 5 days 
later by qPCR analysis of (A) Bmp ligand and receptor expression, (B) hepcidin 
regulatory genes, and (C) Smads. mRNA expression was normalized to β-actin. 
(D) Western blot analysis was performed on whole-cell extracts of livers from 
VhlF/F and VhlF/F;AlbERcre mice treated with tamoxifen (TM) for 5 days and 
examined for pSmad1/5/8 expression. Loading was normalized to GAPDH. n = 6 
to 8 animals per group. Each bar represents the mean ± SE. Asterisks denote 
statistical significance versus control results at P < 0.05 as determined by 













Fig. 4.4.  Hepcidin repression by HIF requires a decrease in C/EBPα protein 
expression. (A) VhlF/F and VhlF/F;AlbERcre mice were treated with tamoxifen (TM) 
and sacrificed either 5 days or 2 weeks following Cre recombination, and liver 
expression of C/EBPα and hepcidin was determined by qPCR and normalized to 
β-actin. (B) Western blot analysis was performed on nuclear extracts to detect 
C/EBPα in VhlF/F and VhlF/F;AlbERcre mice or in the Vhl compound-disrupted mice 
following 2 weeks of tamoxifen (TM) treatment. (C) C/EBPα protein expression in 
the livers of VhlF/F and VhlF/F;AlbERcre mice was examined by Western blot analysis 
1 day following tamoxifen (TM) treatment. (D) Mice were infected with 
recombinant C/EBPα adenovirus (Ad-C/EBPα) and 3 days later examined for 
C/EBPα protein expression by Western blot analysis. Loading was normalized to 
histone H1 or histone H3. (E) VhlF/F and VhlF/F;AlbERcre mice were infected with 
adenovirus for 3 days and then treated with tamoxifen (TM) for an additional 5 
days, and hepcidin expression was assessed by qPCR normalized to β-actin. n = 
6 to 8 animals per group. Each bar represents the mean ± SE. Single asterisks 
denote statistical significance versus control results at P < 0.05 as determined by 






Fig. 4.5.  Proteasomal degradation of C/EBPα is necessary for HIF-
dependent hepcidin repression. (A, B, and C) Huh7 cells were infected with 
Ad-C/EBPα at an MOI of 100 1 day before exposure to hypoxia (1% O2) for 24 h. 
Gene expression was examined by qPCR for (A) hepcidin and (B) C/EBPα, and 
(C) Western blot analysis was performed on whole-cell extracts to detect 
C/EBPα. (D) Western blot analysis for C/EBPα in Huh7 cells infected with Ad-
C/EBPα at an MOI of 100 1 day before exposure to hypoxia (Hyp) (1% O2) and 
10 µM MG132 for 24 h. (E) HEK293A cells were transfected with wild-type or 
S193A mutant C/EBPα expression constructs and exposed to normoxia (Norm) 
or hypoxia (Hyp) for 24 h, and C/EBPα expression was examined by Western 
blot analysis. (F) Liver Vhl knockout mice were analyzed for liver cyclin D1 
expression by Western blot analysis in whole-cell extracts 2 weeks after Cre 
recombination. (G) Control and ethanol-treated animals were examined for liver 
cyclin D1 expression by Western blot analysis in whole-cell extracts. Loading 
was normalized to GAPDH. n = 3 samples per group; the experiments were 
repeated at lest three times. Each bar represents the mean ± SE. Single 
asterisks denote statistical significance versus control results at P < 0.05 as 






Fig. 4.6.  C/EBPα overexpression in vivo blocks repression of hepcidin by 
ethanol treatment. (A) Liver-specific Arnt disruption was induced by tail vein 
injection of adenovirus expressing Cre recombinase (Ad-Cre) 3 days before 
ethanol treatment, and Western blot analysis was performed to detect C/EBPα in 
control and ethanol-treated livers. Protein loading was normalized to histone H3. 
(B) Mice were infected with adenovirus expressing C/EBPα (Ad-C/EBPα) 3 days 
before ethanol treatment, and hepcidin expression was analyzed by qPCR. 
Expression was normalized to β-actin. (C) A schematic diagram illustrating the 
mechanism by which alcohol-induced activation of HIF controls hepcidin 
repression through Cdk-dependent C/EBPα degradation. n = 6 to 8 animals per 








Fig. 4S1.  Adenoviral infection does not induce hepcidin expression.  Mice 
were infected with GFP-expressing adenovirus and analyzed 3 days after 
infection.  Gene expression was examined by qPCR for hepcidin and normalized 
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Conclusions and Future Directions 
 
The work presented in this thesis provides convincing data that local iron 
sensing through the hypoxic pathway is a critical systemic regulator of iron 
homeostasis. Hypoxia-inducible factor 2 alpha (HIF-2α) is an essential regulator 
of iron absorption in the setting of iron deficiency (1). In addition to iron 
deficiency, iron absorption is increased during erythropoiesis, and this was 
thought to be controlled by erythropoietic hepcidin repression (2).  However, the 
work in this thesis extends the role of intestinal hypoxic sensing and HIF-2α as 
the major physiological regulator of iron homeostasis during erythropoiesis. 
Intestinal HIF-2α disruption inhibits the increase in intestinal iron transporters 
during erythropoiesis and blunts the production of red blood cells (RBCs) 
compared to wild-type littermates, likely due to decreased iron availability (3). 
Intestinal hypoxia appears to be the major signal that leads to activation of HIF-
2α during high levels of erythropoiesis.   This is a unique mechanism compared 
to dietary iron deficiency, in which a decrease in intestinal iron levels likely 
causes HIF-2α stabilization in this condition (Erik Anderson, unpublished data). 
In diseases of ineffective erythropoiesis such as β-thalassemia, increased 
iron absorption that leads to iron overload is commonly observed, and again the 
major driving mechanism leading to hyper-absorption of iron was thought to be
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mediated by a decrease in hepcidin expression (4).  To test whether intestinal 
HIF-2α is important in pathological iron absorption in β-thalassemia, thalassemic 
mice were crossed to mice with HIF-2α disrupted in the intestinal epithelium.   
The loss of intestinal HIF-2α completely inhibited the increase in iron absorption 
genes and prevented iron overload in mouse models of β-thalassemia.  In 
addition, loss of intestinal HIF-2α promoted mobilization of liver iron in models of 
erythropoietic stress.  This suggests that inhibition of intestinal HIF-2α could be 
combined with existing treatments to rapidly reduce liver iron levels (Anderson et 
al, 2012 submitted). 
 In addition to local hypoxic effects in the intestine, hypoxia robustly 
represses liver hepcidin expression.  Under physiological conditions that regulate 
hepcidin, such as iron deficiency and erythropoiesis, HIFs are entirely 
dispensable (1) (Matthew Taylor, unpublished data).  While HIF signaling is not 
necessary for physiological hepcidin expression, a pathological condition in 
which hepcidin deficiency contributes to iron absorption and iron overload is 
alcoholic liver disease (ALD) (5).  Several mechanisms have been proposed to 
explain hepcidin repression in this disease (6-9).  However, the mechanism 
remained unclear.  In this thesis we demonstrate that CCAAT/enhancer binding 
protein alpha (C/EBPα), a transcription factor that is essential for hepcidin 
expression (10), is decreased in ethanol loading in a HIF-dependent manner 
(11).  This clearly places hypoxia signaling upstream of hepcidin signaling in 
ALD, revealing new therapeutic targets and reinforcing the central role of hypoxia 
in the regulation of iron homeostasis. 
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The work presented in this thesis clearly demonstrates that hypoxia 
signaling plays an essential role in maintaining systemic iron homeostasis under 
physiological and pathological conditions.  The laboratory is currently working to 
identify novel compounds that inhibit intestinal HIF-2α in vivo, which could be 
added to existing therapies for iron overload to rapidly reduce tissue iron levels.  
In addition, the laboratory is investigating whether targeting intestinal divalent 
metal transporter 1 (Dmt1), a major HIF-2α target involved in iron absorption, 
could be therapeutic in conditions of iron overload. 
This thesis work demonstrates that the intestine, through HIF-2α signaling, 
is both a sensor and regulator of systemic iron homeostasis, and has led to 
further questions that will need to be addressed. While the following sections are 
outside the scope of this thesis work, they will serve as jumping-off points for 
future endeavors to discover additional roles for hypoxia signaling and iron 
homeostasis in the regulation of human physiology and disease. 
 
HIF-2α-hepcidin crosstalk in iron absorption 
 Erythropoiesis and iron deficiency activate intestinal iron absorption, and it 
was previously thought that a decrease in hepcidin was entirely responsible for 
meeting this increased iron demand (12). However, this thesis work clearly 
demonstrates that intestinal HIF-2α is essential for increased iron absorption (3). 
In addition, the function of hepcidin with respect to iron homeostasis requires 
intact HIF signaling (13). While short term decreases in hepcidin expression may 
not be responsible for increased iron absorption, animal work has demonstrated 
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that hepcidin deficiency over a period of time leads to enhanced iron absorption 
and severe iron overload (14). Together the data suggest that HIF-2α must be 
stabilized in the intestine following a chronic decrease hepcidin expression.  
 One condition which is well known to stabilize HIF-2α is enterocyte iron 
deficiency (1).  This could be achieved through upregulation of duodenal Fpn1 
expression, but multiple publications have shown that hepcidin does not directly 
influence stability of Fpn1 in the intestine (13, 18).  This conflicts with the 
observation that hepcidin treatment leads to inhibition of enterocyte iron export 
(19).  One possibility is that hepcidin is able to exert an effect on the activity of 
Fpn1 without directly influencing its stability. Hepcidin could bind to Fpn1 and 
block iron export, and the absence of hepcidin could allow Fpn1 to export iron 
more efficiently.  This possibility was suggested to occur using the human 
intestinal Caco-2 cell line, in which hepcidin treatment blocked iron export without 
influencing Fpn1 protein expression (20).   
 
 If this model is true, then HIF-2α activation by hepcidin deficiency would 
occur through intracellular iron depletion (Fig. 5.1).  Under conditions of normal 
hepcidin expression, hepcidin would interact with Fpn1 and limit its ability to 
export iron.  Blocking iron export will maintain enterocyte iron at high levels, 
allowing prolyl hydroxylase enzymes (PHD) to hydroxylate HIF-2α and lead to its 
proteasomal degradation.  Under hepcidin deficiency, Fpn1 would export iron 
more efficiently, leading to intracellular iron deficiency.  Low intracellular iron 
inactivates the PHD enzymes, stabilizing HIF-2α and subsequent increase in 
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target genes Dmt1, duodenal ferric reductase (DcytB), and Fpn1 (1, 21).  This 
would lead to a robust increase in iron absorption and iron overload that is 
observed with hepcidin deficiency (17). 
 The other known stimulus that can increase HIF-2α activity in the intestine 
is hypoxia (3).  Hepcidin exerts an effect on the erythropoietic compartment, 
given that erythroblasts express the hepcidin receptor, Fpn1 (22).  Hepcidin 
regulates expression of Fpn1 on erythroid progenitors (23).  Thus, hepcidin 
deficiency could lead to increased Fpn1 expression on developing RBCs, 
depleting them of iron and compromising their ability to carry oxygen.  While prior 
publications have shown that Fpn1 expression in erythroid precursors decreases 
as they differentiate, we have been able to detect high levels of Fpn1 protein on 
the membranes of mature RBCs and are able to observe a response to hepcidin 
(Fig. 5.2A).  In addition, a physiological stimulus that reduces hepcidin levels, 
dietary iron deficiency, leads to a substantial upregulation of Fpn1 expression on 
mature RBCs (Fig. 5.2B). 
 To investigate if hepcidin deficiency stabilizes HIF-2α through its effect on 
RBCs, mice were generated which overexpress a green fluorescent protein 
(GFP)-tagged Fpn1 protein (24) which is mutated to be resistant to hepcidin 
degradation (25), specifically in RBCs (26).  This mouse model should mimic one 
effect of hepcidin deficiency, increased expression of Fpn1 on mature RBCs and 
erythroid progenitors.  If this leads to RBC iron deficiency and subsequent 
hypoxia, then intestinal HIF-2α should be stabilized.  Founder lines are currently 
being analyzed.   While iron deficiency and hypoxia are the most well
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characterized inducers of intestinal HIF-2α, it is possible that another unknown 
mechanism could mediate stabilization of HIF-2α by hepcidin deficiency. 
 
HIF and anemia of inflammation 
 In humans, acute infection leads to a drop in serum iron and anemia (27).  
It is thought that this is primarily controlled by hepcidin and its ability to degrade 
the iron exporter, Fpn1 (28).  While iron sequestration provides a short term 
benefit during inflammation by depriving pathogens of this critical nutrient (29), 
anemia becomes a critical factor in the setting of chronic disease (30).  
Intriguingly, the model of intestinal HIF-2α overexpression leads to substantial 
iron overload (1) despite having appropriate increases in hepcidin expression in 
response to iron loading (Yatrik Shah, unpublished data).  This raises the 
possibility that intestinal HIF-2α overexpression could overcome the effect of 
hepcidin on iron sequestration.   
 In a model of zymosan-induced generalized inflammation (ZIGI) (31) 
serum iron drops precipitously following zymosan treatment  (Fig. 5.3A).  This 
correlates with decreases in both Fpn1 mRNA and protein in the duodenum (Fig. 
5.3B-C).  Since mice overexpressing HIF-2α in the intestine greatly increase 
Fpn1 expression (21), it is possible that these mice would be protected from the 
drop in serum iron observed after zymosan treatment.   
 Future plans entail assessing newly weaned wild-type or intestinal HIF-2α 
overexpressing mice following zymosan treatment. Serum iron levels, intestinal 
iron transporter gene expression, and tissue iron levels will be assessed. If the 
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drop in serum iron is attenuated by intestinal HIF-2α overexpression, mice could 
be allowed to survive past 24 hours in order to determine if the subsequent 
anemia observed in this model is also affected (31).  If stimulating iron absorption 
through increasing intestinal HIF-2α counteracts the anemia, intestinal HIF-2α 
agonists could be used therapeutically in critically ill patients. 
 
Intestinal HIF-2α in the mothers of nursing neonates is essential for 
production of milk with adequate iron concentrations 
 Iron deficiency is common in infants that are breastfed, particularly in 
developing countries, which can lead to anemia (32, 33).  Iron absorption is very 
efficient in young mammals, likely due to the importance of iron in early 
psychomotor and cognitive development (34).  Thus, iron deficiency in suckling 
infants must be due to low levels of iron in breast milk.  Maternal iron absorption 
is increased during pregnancy, but maternal iron absorption postpartum has not 
been investigated.  Supplementing infant diets with iron is effective in reducing 
the prevalence of anemia in infants, but widespread infant dietary 
supplementation could be difficult to achieve in developing countries where risk 
of iron deficiency is greatest (35).  Previous studies have demonstrated that a 
maternal diet deficient in macro and micronutrients translates to deficiencies in 
milk nutrient content and lower weight gain in breastfed infants (36).  Thus, 
maternal dietary intervention, either through distribution of knowledge or 
supplements, could substantially improve infant health, growth, and development 
in developing countries.  
	  
	  113	  
 A healthy person will absorb 1-2 mg/day of iron from the diet, mostly in the 
duodenum of the small intestine (37).  At 1 day postpartum, breast milk iron 
concentrations are approximately 90 µg/dL, which declines to approximately 30 
µg/dL at 6 months postpartum (38).  Infant breast milk consumption is on 
average about 800 mL/day, which will deplete a lactating mother of about 700 
µg/day of iron early after birth, and about 250 µg/day as infants approach 
weaning age (39).  Despite this high demand of iron from the mother, 6 months 
postpartum maternal iron levels are increased compared to 1 day postpartum 
(38).  Together, these data suggest that lactating mothers may increase iron 
absorption in order to meet this high demand for iron.  Investigating this 
possibility will lead to new knowledge that can be used to combat anemia and 
growth retardation in infants.  
 It is well-established that intestinal HIF-2α deletion (Hif-2αΔIE) in mice 
blocks adaptive increases in iron absorption (1, 3, 21).  Over the course of 
breeding these mice, it was observed that mice born to mothers lacking intestinal 
HIF-2α expression have a defect in hair growth and weigh significantly less than 
weanlings from wild-type mothers, which are related to iron deficiency (40) (Fig. 
5.4A and C).  Fostering mice born from a Hif-2αΔIE mother to a wild-type mother 
leads to complete recovery of the phenotype, demonstrating that the phenotype 
is not due to fetal development (Fig. 5.4B).  One explanation for this recovery 
could be due to some nutritional deficiency in breast milk from Hif-2αΔIE mothers.  
Since it is known that these mice have a deficiency in iron absorption, breast milk 
was collected and pooled from wild-type and Hif-2αΔIE mothers with pups that 
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were 7 days old and analyzed for iron content.  Milk from Hif-2αΔIE mothers is 
severely deficient for iron (Fig. 5.4C).  While these data are preliminary, they 
strongly suggest that studying iron absorption in mothers with nursing offspring 
could improve knowledge and prevent anemia in infants worldwide. Moreover, 
there are many foods that inhibit iron absorption, including eggs, cocoa, coffee, 
tea, and nuts (41-43).  On the other hand, ascorbic acid can enhance dietary iron 
absorption (44). Investigating the mechanisms of maternal iron absorption 
postpartum could lead to dietary interventions which could prevent anemia and 
developmental delays in breastfed infants. 
 
Steap4 in the intestine 
 DcytB is the only known mammalian ferric reductase in the intestine which 
responds to increases in systemic iron requirements. However, deletion of DcytB 
does not affect iron homeostasis, suggesting that other ferric reductases must 
compensate. Since intestinal deletion of HIF-2α completely abrogates ferric 
reductase activity in the intestine following an increase in systemic iron 
requirements, mice overexpressing HIF-2α are an ideal model to identify 
additional ferric reductases in the intestine. Microarray analysis from duodenal 
mRNA from wild-type mice compared to mice overexpressing HIF-2α identified 
six-transmembrane epithelial antigen of prostate 4 (Steap4) as a gene highly 
induced by HIF-2α (Fig. 5.5A)(1). Steap4 contains metalloreductase activity (45). 
 Similar to other proteins involved in iron homeostasis, Steap4 expression 
in the intestine requires HIF-2α (Fig. 5.5B). However, analysis of protein 
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expression demonstrates that Steap4 is only induced in the colon, despite 
loading substantially more duodenal extract (Fig. 5.5C).  This suggests that 
Steap4 is unlikely to play a role in iron homeostasis, but could be involved in 
homeostasis of the colon. Consistent with these data Steap4 is highly induced in 
intestinal samples from ulcerative colitis patients compared to normal controls. 
Moreover, Steap4 is induced in mouse models of colitis (Fig. 5.5D).  These data 
suggest that Steap4 may be an important protein linking nutritional cues to 
inflammation. To directly investigate the role of Steap4 in the intestine in vivo, 
transgenic mice were generated which overexpress a Steap4-GFP fusion protein 
(46) under control of the villin promoter (47), which drives expression throughout 
the entire intestine.  Mouse lines with both high and moderate expression of the 
transgene were identified and confirmed by quantitative polymerase chain 
reaction (qPCR) for transgene mRNA, Western blot for the fusion protein, and by 
the functional reductase assay using nitrotetrazolium blue (NBT) (1) (data not 
shown).  Currently these mice are being crossed to the C57BL/6 background, 
and we plan to assess the role of Steap4 in mouse models of colitis and intestinal 
tumors (48). 
  
Regulation of heme iron absorption 
 The vast majority of literature on iron absorption focuses on dietary non-
heme iron, despite heme iron making up the majority of iron absorbed from a 
Western diet (49).  While mechanisms of non-heme iron absorption are very well 
characterized (50) little is known about how heme iron absorption is regulated.  
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One potential mechanism for heme to enter the enterocyte is through the heme 
transporter, solute carrier family 46 member 1 (Slc46a1) (51).  However, it was 
subsequently determined that the primary role of Slc46a1 is to serve as a folate 
transporter (52).  It was also thought that heme taken up in this manner could be 
exported through feline leukemia virus subgroup C cellular receptor 1 (FLVCR1), 
a heme exporter (53).  However, an experiment in which dogs were administered 
an intragastric dose of radiolabeled hemoglobin demonstrated that most of the 
radiolabeled iron in circulation was present in non-heme form, suggesting that 
heme is broken down in the enterocyte prior to export to the circulation (54). 
 Electron microscopic data indicate that heme uptake in the intestine 
occurs through endocytosis, and heme is broken down within endocytic vesicles 
(55).  While no receptor for heme has been identified in the intestine, the 
breakdown of heme is known to be catalyzed by heme oxygenase 1 (HO-1) (56).  
Following release of iron from heme, it must be exported from the vesicle into the 
cytosol and into circulation by Fpn1 (57).  Interestingly, iron deficiency increases 
dietary heme absorption, although mechanistically it is not known how this is 
achieved (58).  One possibility is that HIF-2α, which mediates adaptive increases 
non-heme iron absorption following iron deficiency, could also be involved in 
increasing heme absorption. 
 HIF-2α may promote heme iron absorption through a number of 
mechanisms.  Dmt1 is a HIF-2α target (1), and could be involved in the release of 
iron from endocytic vesicles after heme breakdown.  Also, Fpn1 is a HIF-2α 
target (21) that is necessary for export of iron from the enterocyte to the serum.  
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In addition, HIF-2α could regulate the as yet undiscovered heme receptor, since 
many genes are regulated by HIF-2α that have been identified by microarray but 
not yet characterized (21).  To test this, mice that overexpress HIF-2α in the 
intestine will be maintained on a diet deficient for non-heme iron, but enriched 
with heme iron.  After maintaining mice on the diet for two weeks, they will be 
analyzed for serum, intestinal, and liver iron content.  If iron stores are higher in 
the HIF-overexpressing mice, then it would suggest that HIF-2α is an important 
mediator of increased heme absorption. 
 It will also be important to determine if loss of HIF-2α affects heme iron 
absorption as well.  To test this, we will first determine a diet that is deficient in 
non-heme iron, but is supplemented with a small amount of heme iron, such that 
the intestine activates genes involved in the response to iron deficiency.  Wild-
type mice should be able to increase heme absorption and maintain normal iron 
levels.  Mice lacking intestinal HIF-2α on the diet should become progressively 
anemic if HIF-2α is important for adaptive increases in heme iron absorption.  
Regardless of the data, the diets used for these experiments offer a novel model 
for investigating the mechanisms of heme iron absorption, as no laboratory has 




 The data in this thesis challenge the central role of hepcidin in regulating 
iron homeostasis.  Hepcidin expression certainly correlates very well with 
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systemic iron levels and requirements, and animal models of hepcidin knockout 
or overexpression lead to iron overload and anemia, respectively.  The present 
work demonstrates that HIFs are local effectors controlling the response to 
systemic iron levels, and that HIFs control both hepcidin expression itself as well 
as the response to fluctuations in hepcidin expression.  Hepcidin could be used 
therapeutically to limit iron levels, but as a consequence hepcidin traps iron in 
tissues such as macrophages, liver, and bone marrow, which could lead to iron-
mediated oxidative stress and tissue damage.  Targeting HIF-2α in the intestine, 
however, only affects the iron entering the body, which is then regulated by 
hepcidin and other factors to ensure proper distribution in a way that limits organ 
damage.  Further studies into pharmacologic HIF-2α inhibitors or agonists could 

















Figure 5.1.  Putative model by which hepcidin regulates HIF-2α expression.  
Under conditions of normal hepcidin expression, intracellular iron levels are kept 
high by hepcidin’s ability to block export of iron through Fpn1.  This allows prolyl 
hydroxylase enzymes (PHD), which require iron as a cofactor, to hydroxylate 
HIF-2α, leading to its degradation.  Under conditions of hepcidin deficiency, the 
inhibitory effect of hepcidin on Fpn1 function is relieved, leading to a depletion of 
intracellular iron.  This inactivates the PHD enzyme, leading to HIF stabilization 
and activity.  HIF then increases expression of Dmt1, DcytB, and Fpn1, leading 








Figure 5.2.  Hepcidin acts on mature RBCs to degrade Fpn1.  RBCs were 
collected from an animal in K2EDTA tubes and aliquoted.  RBCs were then 
incubated with the indicated hepcidin concentrations for 24 hours before 
harvesting cells and performing a membrane protein extraction. A) Fpn1 protein 
was detected by western blot on membrane and cytosolic fractions.  Blood was 
collected from mice maintained on a normal diet, or an iron-deficient diet (3.5 
ppm Fe3+) for 2 weeks. B) Fpn1 protein was detected by western blot from 
membrane extracts.  (dark) indicates longer exposure time.  Even protein loading 














Figure 5.3.  Duodenal Fpn1 expression decreases during the hypoferremia 
of inflammation.  Mice were injected with 0.64 mg/g zymosan and analyzed 24 
hours later. A) Serum iron levels in control and zymosan-treated (ZIGI) mice.  
mRNA was extracted from the duodenum and reverse transcribed. B) qPCR 
analysis of Fpn1 expression in the duodenum.  Expression was normalized to β-
actin.  Membrane protein was extracted from the duodenum and analyzed. C) 
Fpn1 expression in the duodenum of control and ZIGI mice.  Even loading was 













Figure 5.4.  Maternal iron absorption determines offspring growth and 
development.  Mice from Hif-2αF/F and HIF-2αΔIE mothers were compared after 
weaning.  A) Mice weaned from Hif-2αΔIE mothers demonstrate a defect in hair 
growth.  B) Fostering mice from Hif-2αΔIE mothers to Hif-2αF/F mothers at 1 week 
of age rescues the hair growth defect.  C) Milk non-heme iron content pooled 
from Hif-2αF/F mothers and Hif-2αΔIE was analyzed.  Pups from Hif-2αF/F and Hif-












Figure 5.5.  Steap4 is induced in the intestine of HIF-overexpressing mice 
(VhlΔIE).  Mice with targeted disruption of Vhl in the intestine (VhlΔIE) were 
analyzed for Steap4 expression by qPCR.  A) Steap4 mRNA is upregulated in 
both the small intestine and colon of VhlΔIE mice.  B) Loss of HIF-2α in addition to 
Vhl (VhlΔIE Hif-2αΔIE) completely abrogates the induction of Steap4 mRNA.  C) 
Western Blot analysis of Steap4 demonstrates colonic, but not duodenal 
induction of Steap4 protein.  D) Steap4 expression in the colon of mice treated 
with C. rodentium (C. rod).  Coomassie stain was used as a loading control.  
mRNA expression was normalized to beta-actin.* p-value < 0.05 as determined 
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